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1. INTRODUCTION 
 
1.1 CELLULAR SENESCENCE 
Senescence was formally described in 1965 by Hayflick, as a process that limits 
the proliferation of human fibroblast in culture [1]. Hayflick experiments showed 
that human fibroblast, over many cell doublings, underwent a decline in cell 
proliferation. Eventually, all cells in the culture lost the ability of divide [2]. A 
phenotype similar to senescence described by Hayflick was observed on 
overexpression of an oncogenic version of H-Ras (H-Ras
V
12) in fibroblast in 
vitro. Normal cells forced to express high levels of the oncogene, rather than 
proliferate, stopped dividing and suffered morphological and molecular changes 
similar to those observed by Hayflick [3]. Based on these observations, cellular 
senescence refers to the essentially irreversible growth arrest that occurs in cells 
subjected to several kinds of stress in order to limit the proliferation of damaged 
cells or of cells reaching the “Hayflick limit”.    
Cellular senescence limits the proliferation of cells, therefore it can be induced 
only in mitotic cells (epithelial, stromal and vascular cells that comprise the major 
renewable tissues and organs such as skin, intestines, liver and kidney). 
Recently it has been demonstrated the presence of senescent cells even in some 
kinds of tumors, such as pre-malignant tumors and tumoral cells at early stage of 
tumorigenesis [4, 5, 2, 6].  
Senescent growth arrest is essentially irreversible, in contrast to what observed in 
quiescent cells; in fact it was verified that senescent cells cannot be stimulated to 
proliferate even in the presence of growth factors [2].  
Only after inactivation of pathways that are responsible to regulate and maintain 
senescence phenotype (for example p53-p21 and p16
INK4A
-pRb pathways) can be 
reverted the proliferative arrest that characterized these cells. For example, 
inactivation of the p53 pathway permits senescence reversal [7, 8], likewise 
inactivation of some interleukins also abrogates the proliferative arrest [9, 10]. 
Another feature of senescent cells, which distinguishes them from quiescent cells, 
is that senescent cells are metabolically active even if not proliferate.  
Senescent cells become resistant to cell-death signals, such as apoptotic signals, 
and they acquire widespread morphological changes, as well as changes in gene 
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expression, distinguishing them from proliferating cells. Taken together, all these 
changes define what is called “senescent phenotype” [2]. 
Senescent can be induced by many stimuli (Fig.1) 
 
 
 
 
 
 
 
 
 
 
Fig.1: Mitotically competent cells respond to various stressors by undergoing cellular senescence 
[2]. 
 
It is possible to distinguish several type of senescence, based on the type of 
stimuli  that induce it: 
1) Replicative Senescence: this type of senescence is caused by telomere 
erosion, due to the gradual loss of DNA at the ends of chromosomes during each 
S phase. It is this type of senescence that Hayflick described in your experiment 
[1].    
2) Premature cellular senescence: senescence can be induced in the absence 
of telomere loss or dysfunction. This type of senescence has been termed 
premature, since it arises before replicative senescence. Several kinds of stress can 
determine the activation of this type of senescence, hence it is possible to 
distinguish between:  
 Stress-induced senescence: in vitro premature senescence can result from 
inadequate culturing conditions [11, 12], oxidative stress [13, 5, 14] and 
exposure to agents that cause DNA damage such as chemotherapeutic drugs 
and ionizing radiation [2].  
 Oncogene-induced Senescence (OIS): normal cells respond to oncogenes 
over-expression or loss of tumor suppressor genes by undergoing 
senescence [3]. 
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  PTEN loss-induced senescence (PICS): this type of senescence is rapidly 
induced as a consequence of loss of PTEN tumor supppressor gene [6]. 
 
Cell senescence is generally accompanied by morphological changes, that 
facilitate the identification both in vivo and in vitro. 
To date, an exclusive marker that can be used to identify the activation of cellular 
senescence as not yet been defined, and on the other hand it is clear that not all 
senescent cells express the same markers [2, 15].   
The marker that is commonly used to identify senescent cells is Senescence-
Associated β-galactosidase (SA-βgal) [26]. It has been demonstrated that 
senescence cells are characterized by an increase in SA-β-GAL activity. Its 
increase activity in senescent cells derives from lisosoma β-D-galactosidase, 
which is encoded by the GLB1 gene [27]. Acid β-D-galactosidase i san eukaryotic 
hydrolas localized in the lysosome. It clave β-linked terminal galactosyl residues 
froma wide range of substrates (gangliosides, glycoproteins and 
glycosaminoglycans). The increase in SA-β-GAL activity in senescent cells is 
likely due to an expansion of the lysosomal compartment, as a result of the 
accumulation of damaged macromolecules in lysosomes [28]. The increase 
expression of β-D-galactosidase and the expansion of the lysosomal compartment, 
cause an increase in β-galactosidase activity that can be measured also at 
suboptimal pH6 [27]. Senescent cells can be easily identified with respect to 
proliferating cells using a cytochemical assay that evaluate the activity of β-
galactosidase.  
The hallmark of cellular senescence is an inability to progress through the cell 
cycle. Senescent cells arrest growth, usually with a DNA content that is typical of 
G1 phase [16]. The feature and stringency of the senescent growth arrest vary 
depending on the species and the genetic background of the cell. For example, it 
has been shown that mouse fibroblast senesce with a G2/M DNA content as a 
result of a defect in the stress-signaling kinase MKK7 [17]. 
Likewise, oncogenes overexpression cause a fraction of cells to senesce with a 
DNA content that is typical of G2 phases [18, 19].  
Cell senescence is generally accompanied by morphological changes, which allow 
distinguishing them from proliferating and terminally differentiated cells. 
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In general, senescence cells increase in size, in some cases a two-fold increase 
compared to non-senescence cells it has been observed. Furthermore, cells can 
become large, flat and multinucleated.   
Beside those that are considered common alterations of senescent cells, there are 
morphological changes that are peculiar to a particular type of senescence.   
For example, a flat cell phenotype is commonly seen in cells undergoing H-
Ras
V
12-induced senescence [3, 20], stress-induced senescence [21] or DNA-
damage induced [22]. Cell senescing due to BRAF
E600
 expression or the silencing 
of p400, however, acquires a more spindle-shaped morphology [23, 24]. 
Melanocytes undergoing H-Ras
V12
-induced senescence display extensive 
vacuolization as a result of endoplasmic reticulum stress caused by the unfold 
protein response (UPR) [20]. Furthermore, vacuolization it has been demonstrated 
in fibroblast underwent H-Ras-induced senescence, where it has been 
demonstrated the involvement of mitochondria in the regulation of cellular 
senescence [25].  
Cellular senescence can be associated with an altered chromatin structure, at least 
in vitro. It has been demonstrated that cycling or quiescent cells, labeled with 
DNA dyes such as DAPI (4‟,6-diamidino-2-phenylindole) display overall 
homogenous staining patterns, instead senescent cells often show strikingly 
different punctuate pattern [29]. These nuclear foci which characterized senescent 
cells are called SAHFs (Senescence-Associated Heterochromatic Foci), and 
correspond to highly compact heterochromatic regions. These SAHFs are 
specifically enriched in proteins such as histone H3 methylated on Lys 9 
(H3K9me) and HP1 (heterochromatin protein 1).  It was verified that SAHFs are 
formed in proximity of the promoters of several E2F target genes, which are then 
silenced [2, 29].  
In this way, SAHFs silence the expression of genes that are needed for cell cycle 
progression, thereby contributing to the block of cell proliferation. The p16
INK4A
-
pRB regulates the SAHFs formation [29]. 
Cells undergoing senescence exhibit profound changes in their transcriptomes. As 
a result senescent cells secrete numerous factors, such as chemokines, growth 
factors and proteases [5, 10, 30]. It was verified that these factors have autocrine 
activities on the cells which they were secreted and a paracrine action on 
surrounding cells. These factors can affect surrounding cells by activating signal 
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transduction pathways that may lead to multiple pathologies including cancer 
[30]. Factors secreted by senescent cells constitue the SASP (Senescence 
associated secretory phenotype). 
SASP factors can be divided into the following categories: 
1) soluble signaling factors (interleukins, chemokines and growth factors); 
2) secreted proteases; 
3) secreted insoluble proteins and extracellular matrix components (ECM). 
A recent study indicates that, for the induction of several SASP factors, persistent 
DNA damage is required. Because DNA damage is typical of some but not all 
kind of senescence, the SASP is produced only when senescence is accompanied 
by the activation of DDR [31].  
 
1.1.1  Replicative Senescence 
Whit the expression “Replicative senescence” we refer to senescence induced in 
normal cells which are reaching the “Hayflick Limit” [1]. The proliferative arrest 
is caused, as previously discussed, by telomere erosion, an event that in 
mammalian cells occurs at the end of each replicative cycle. Telomeres are 
stretches of repetitive DNA (5‟-TTAGGG-3‟) and associated proteins that cap the 
ends of linear chromosomes and protect them from degradation or fusion by 
DNA-repair processes [2]. Telomeres length is maintained by specific enzyme 
called telomerase. Most normal cells do not express telomerase, or express it at 
levels that are too low to prevent telomere shortening [2]. Moreover, DNA 
polymerase cannot completely replicate DNA ends, a phenomenon called the end-
replication problem. As a consequence, cells lose 50-200 bp of telomeric DNA 
during each S-phase. When telomeres reach a critical minimal length the 
replication is blocked and this phenomenon triggers the activation of DNA 
damage response (DDR). The DDR enables cells to sense damaged DNA, 
particularly double strand breaks (DSBs), and to respond by arresting cell-cycle 
progression and repairing the damage if possible [2, 10]. The DDR is associated 
with the appearance of SAHFs, at the level of which are located multiple proteins. 
Multiple proteins participate in the DDR, including protein kinases (ATM (ataxia 
telangiectasia mutated) ATR(ataxia telangiectasia  and Rad3 related) CHK1 e 
CHK2 (checkpoint kinase 1 and 2), adaptor proteins (53BP1 e MDC1 (mediator 
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of DNA damage checkpoint protein-1)) and chromatin modifiers, for example γ-
H2AX. 
The kinases CHK1 and CHK2 are responsible to propagate the damage signal to 
effector molecules such as the phosphatase CDC25 and p53. The effector 
molecules halt the cell cycle progression. If DNA damage exceeds a threshold, 
cells are destined to undergo either apoptosis or senescence; the severity and the 
type of the damage are important factor that can determine the activation of 
senescence instead apoptosis [32]. 
In addiction to p53, it was demonstrated that p16
INK4A
-pRB pathway is essential 
for induction of senescence [33,34]. The relative contribution of these pathways to 
senescence depend on cell type (Fig. 2). 
 
 
 
 
Fig.2: Replicative senescence is driven by telomere erosion, and can results in activation of p16 
and/or p53 [6] 
 
The dependence of replicative senescence on telomere shortening is evident from 
its bypass by the ectopic expression of the catalytic subunit of the telomerase 
holoenzyme (hTERT). This enzyme is responsible to elongates telomeres and then 
to block the induction of senescence [2]. The limited life span of most primary 
cells is explained by the fact that, in contrast to stem cells, telomerase is not 
express or is express at low level in human somatic cells [35]. Likewise, tumor 
cells often express telomerase [36] or elongate their telomeres through a 
mechanism termed alternative lengthening of telomeres (ALT) [37].  
   
1.1.2 Oncogene-induced Senescence (OIS) 
Normal cells respond to oncogenes by undergoing senescence. This phenomenon 
was observed for the first time, in normal human fibroblast expressed an 
oncogenic form of Ras (H-Ras
V12
) oncogene [3].  
This type of senescence, that is induced prior of replicative senescence, is call 
Oncogene-Induced Senescence (OIS). To date, it was shown that other members 
of the Ras signalling pathway, such as RAF, MEK, MOS and BRAF, as well as 
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pro-proliferative nuclear proteins (E2F-1), cause senescence when overexpressed 
or expressed as oncogenic versions [3].  
Recently, it has been shown that even loss of tumor suppressor genes can trigger 
senescence in mouse and human cells. This is the case of INK4A (Inhibitor of 
cyclin-dependent kinase 4A), NFR or ARF(alternative reading frame). 
It has been established that cells underwent OIS, respond to oncogenic signalling 
trigger a DDR, which is associated with hyperproliferation and DNA hyper-
replication [6, 18]. 
Although the mechanism that induced DDR in OIS is different from that of 
replicative senescence, effectors and primary pathways activated are the same 
[32]. In fact, cells underwent OIS are characterized by SAHFs formation, indeed 
OIS fails in cells lack ATM activity or when cells cannot sense DNA damage or 
transduce DDR signals to p53 [18]. Several experimental data have demonstrated 
that p53 and p16
INK4A
-pRB pathways are involved in OIS activation. The relative 
contribution of these pathways to OIS depends on cell type [6]. For example, in 
murine cells, inactivation of p53 or its upstream regulator, p19
ARF
 , is sufficient to 
bypass H-Ras 
V12
 induced senescence [38, 3]. Instead, in human cells p16 
INK4A
 it 
seems to play a more prominent role than p53 in regulating OIS activation, in fact 
it has been shown that some cells depend solely on this pathway for OIS 
regulation[34] (Fig. 3). 
 
 
 
 
 
 
Fig.3: In OIS, the activation of p53 is driven by stabilization through phosphorylation by DDR 
and by ARF-mediated stabilization [6] 
 
Although most of extant knowledge about OIS refers to in vitro experiments, 
some mouse models provide physiological evidence for OIS in vivo [6]. Taken 
together, these studies demonstrate that senescence is a primary response that is 
elicited to limit tumour progression, at least in tumour cells at early stage of 
tumorigenesis [6]. In 2005, four groups simultaneously reported evidences on the 
protective physiological role of OIS in vivo. This was shown for murine lung 
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adenomas, T-cell lymphomas, prostate tumors, as well as human benign 
melanocytic nevi [39-42] that are characterized by a low proliferative index and 
elevation of SA-β-Gal activity, as well as by the induction of some senescence 
markers. For example, nevi are benign melanocytic tumors that generally lack 
proliferative activity. They are commonly characterized by mutation in BRAF 
gene (generally BRAF
V600E
) [43], Michaloglou and collaborators showed that the 
cell cycle arrest of human nevi has hallmarks of OIS: nevi undergo long-term cell 
cycle arrest, express elevated level of p16 and display increased SA-β-Gal 
activity. These results indicate that OIS in nevi acts as a barrier to melanoma 
development [44, 45] 
 
1.1.3 PTEN-Loss Induced Cellular Senescence (PICS) 
A senescence response, recently characterized is PICS (Pten-loss Induced 
Senescence). PICS is rapidly induced after loss of PTEN, it is distinct from OIS 
on several dimension. In fact PICS is induced even in absence of DDR and does 
not follow an initial phase of DNA hyper-replication [46]. 
PICS can occur in cells that are treated with aphidicolin, a molecule that block S-
phase entry and prevents DNA replication [46]. Instead, in H-RAS
V12
 –induced 
senescence, aphidicolin treatment is responsible to abrogate senescence [18].  
Furthermore, the SAHFs formation is not observed in PICS, in fact cells do not 
respond to loss of PTEN activating a DDR; and inhibition of ATM has not effect 
on PICS induction [46].  
Similar to OIS, p53 have a primary role in PICS, but it was shown that p53 up-
regulation is caused by mTOR-mediated translation [46,47]. Several experiments 
have demonstrated that ARF is not involved in p53 regulation in PICS, differently 
to what observed in OIS [46, 47, 48,49]. 
PTEN regulate PICS activation even due to its nuclear function. It has been shown 
that nuclear PTEN acts up-regulating INK4 through the regulation of ETS2 [50]. 
PTEN loss driver senescence from two perspectives: 
1) through p53 up-regulation as result of mTOR hyper-activation; 
2) through INK4A up-regulation as result of disassembly of the CDH1-
containing anaphase-promoting complex (APC/CDH1) and accumulation of ETS2 
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As in the case of OIS, even PICS can have an important role in limiting the 
transformation of early lesions to malignant cancer, almost in prostate cancer [3]. 
(Fig.4) 
 
 
 
 
Fig.4: Model of PICS; p53 regulation is mainly mediated by mTORC1. In addiction, the ETS2-
INK4A pathway is also required for senescence induction [6] 
 
1.1.4 Stress-induced  Senescence 
Different type of stress can induce senescence. For example, in vitro senescence 
can result from inadequate culture conditions, such as abnormal concentration of 
nutrients and growth factors or the presence of ambient of O2 levels [10, 2].  
Severe DNA damage, especially damage that creates DSBs, cause many cells to 
undergo senescence [51, 52]. Oxidative stress, citotoxic agent, chemioterapeutic 
drugs and ionizing radiation are responsible to induce senescence as a 
consequence of activation of DDR [52, 53]. Many chemotherapeutic drugs cause 
severe DNA damage, and then induce senescence in normal cells but also in 
tumor cells in vitro and in vivo [53]. 
Mouse models demonstrated that tumor cells with wild type p53 are more likely 
to senesce in response to chemotherapy than tumor cells with mutant p53, at least 
in cell culture and cancer-prone mouse models [54,55,56]. At the same time, 
exposure to ionizing radiation can induce senescence in normal cells and tumoral 
cells. Similarly, the exposure to ionixing radiation is able to activate a senescence 
process in normal cells as well in tumor [52, 53]. An important therapeutic 
implication that can derived by these observation is that DNA damage therapies, 
such as radiotherapy and chemotherapy, are more likely efficacious in tumours 
that can maintain the capacity to senescence, for example in tumor cells that not 
present mutations in  p53 e p16
INK4A
-pRB pathways [53,54, 55, 56]. 
 
1.1.5 The regulators of cellular senescence: p53-p21 and p16
INK4A
-pRb 
pathways 
Independently from the stimuli that induced senescence, p53-p21 and p16
INK4A
-
pRB pathways are directly involved in establish the senescence growth arrest and 
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to regulate the appearance of the morphological modification typical of 
senescence cells [2]. 
These pathways interact but can independently halt cell-cycle progression. In fact, 
different stimuli can lead to activation of one or the other pathway. In addition the 
propensity with which cells engage p53-p21 or p16
INK4A
-pRB pathways is cell 
type and species-specific [2]. 
Finally, although most cells senesce owing engagement of p53-p21 or p16
INK4A
-
pRB pathways, or both, there are examples of senescence that is independent of 
these pathways [24,57]. 
In general, stimuli that generate DNA damage or that activate DDR, induce 
senescence primarily through the p53 pathway.   
p53 is regulated at multiple point, for example by MDM2, an E3-ubiquitin protein 
ligase which facilitates p53 degradation via proteasoma.  Another p53 regulator is 
ARF, which inhibits MDM2 activity [58]. When activated, p53 induced the 
growth arrest through p21 expression. p21 is a cyclin-dependent kinase inhibitor  
which acts on cyclinE-A/Cdk2 complexes (Fig.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4: Nuclear and cytoplasmatic activity of p21 
 
Stimuli that produce a DDR can also engage the p16
INK4A
-pRB pathway, but this 
usually occurs secondary to engagement of the p53 pathway [59,60].  
Nonetheless, some senescence-inducing stimuli act primarily through the 
p16
INK4A
-pRB pathway. This is the case of H-Ras induced senescence, in which 
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oncogenic Ras induces p16 expression by activating ETS transcription factors 
[62]. 
The p16
INK4A
-pRB pathway is crucial for generating SAHFs, which silence the 
genes that are needed for cell proliferation [61]. SAHFs require several days to 
develop, during which time there are transient interactions among chromatin-
modifying proteins such as HIRA (HIstone Repressor A), ASF1a (Anti-Silencing 
Function 1a) and HP1. Once established, SAHFs no require p16 or pRb for 
maintenance. Although SAHFs are not present in all senescence cells, the 
p16
INK4A
-pRB pathway might establish chromatin states that are functionally 
equivalent to SAHF [2]. 
Even p53-p21 pathway can be induced without the involvement of DDR, as 
demonstrated in PICS where p53 increase expression depends on mTOR-hyper-
activation [46]. 
p16 and p21 are both cyclin-dependent kinase inhibitor (CDKIs) and are 
responsible to halt cell-cycle progression. p21 acts primarily as “universal” 
inhibitor of cyclin-Cdks complexes, instead p16 acts on cyclin D-Cdk4-6 
complexes. p16 and p21 can keep pRb in an active, hypophosphorylated form. In 
proliferating cells, pRb is maintained in a hyperphosphorylated inactive form by 
cyclin-Cdk complexes, thereby pRb cannot inhibit the transcriptional factor E2F. 
The final effect of pRb inactivation is the transcription of genes which control cell 
proliferation.  
 
1.1.6 Senescence in vivo  
Much of the current knowledge on the causes and consequences of senescence 
derives from in vitro studies. Only during the past decade cellular senescence has 
been shown to occur in vivo [2]. In rodents, primates and humans, senescence 
cells are found in many renewable tissues, such as vasculature, haematopoietic 
system, many epithelial organs and the stroma [2,33, 63] 
Cells that express senescence markers are relatively rare in young organisms, but 
their numbers increase with age. Senescence observed in age tissues is caused 
mainly by telomere dysfunction (replicative senescence).   
Cells that express the typical markers of a senescent cells are found at sites of 
chronic age-related pathology, such as osteoarthritis and atherosclerosis [64,65].  
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In addition, senescent cells are associated with benign dysplastic or preneoplastic 
lesions [24,66,67,68] and benign prostatic hyperplasia [69] but not with malignant 
tumours. As previously discuss, senescent cells can be found in normal ad tumour 
tissues following DNA damaging chemiotherapy [53,54,55,56]. Taken together 
these results support the hypothesis that senescence suppress or limiting the 
development of cancer.        
 
1.1.7 Senescence and tumorigenesis  
Although initially the hypothesis that senescence could be correlated with 
tumorigenesis originated a lively debate, nowadays the idea that senescence is a 
powerful physiological mechanism, able to block tumour proliferation is quite 
well established. Several independent studies performed in human as well as in 
animal models, have supported the idea that senescence, as well as apoptosis, is an 
efficient mechanism that cells can used to suppress tumour proliferation [70]. The 
presence of senescent cells had been identified in animal models and in human, in 
close association with pre-malignant stages of tumorigenesis.  
The original identification of senescent tumour cells was obtained from lung 
adenomas, pancreatic intraductal neoplasias and melanocytic nevi associated with 
the presence of oncogenic BRAF
V600E
, which are all pre-malignant tumours [15, 
4]. Senescent cells have been found in hyperplastic lesions such as benign 
prostatic hyperplasia [69], and also in a familial cancer syndrome known as 
neurofibromatosis type 1, caused by loss-of-function mutations in NF1 tumour 
suppressor gene [71].  
Taken together these data emphasize a close association between senescence and 
tumour, but it is important to underline that senescence is associated with tumours 
at pre-malignant stage of tumorigenesis, but not with malignant tumours [4]. As 
previously discuss, senescent cells are identified initially in pre-malignant 
tumours such as lung adenomas, pancreatic intraductal neoplasias and nevi 
melanocytic [68,66,39]. By contrast senescence was absent in their corresponding 
malignant stages, which are respectively lung adenocarcinomas, pancreatic ductal 
adenocarcinomas and melanomas [68,66,72]. The different behaviour observed in 
pre-malignant lesions compared to aggressive tumor is due to the fact that in most 
cases the differentiation towards a malignant phenotype is associated to an 
inhibition of p53 and p16 pathways. 
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It would however be incorrect to conclude that tumoral cells have lost their ability 
to senesce. It is possible to induce senescence also in malignant tumoral cells if 
correctly stimulated. Interestingly, in animal models, the induction of such a 
process in tumoral cell line can be effective from a therapeutic point of view.   
Initial studies conducted on humans have shown  that senescence can be induce 
after treatment with chemotherapeutic drugs, and the result is regression of the 
malignant phenotype [2].  
In the past few years, the concept of pro-senescence therapy has emerged as a 
novel theraputic approach to treat cancer [6]. To date, are in developing 
therapeutic strategies to activate senescence in tumour cells are under 
development.  
These drugs can be subdivided in several categories [6]: 
1) drugs that can enhance p53 activity and function; 
2) drugs with the ability to modulate the cell cycle machinery, for example drugs 
which act on p27 and pRb;  
3) drugs that target oncogene or tumour suppressor genes;  
4) telomerase inhibitors for the induction of replicative senescence . 
 
Each of these strategies is developed in order to be used alone for senescence 
induction and cancer treatment. However, the idea of using pro-senescence 
strategies in combination with traditional treatment protocols (for example 
chemotherapy and radiotherapy) is emerging, with the aim of combining the 
positive effect of single treatment and then to improve the effectiveness of 
treatment. Such an idea emerged from experiment conducted in mouse model 
affected by lymphomas.  
Mouse model of chemotherapy have shown that MYC-initiated lymphomas 
respond to ciclophosphamide by inducing tumour cell senescence, but the most 
interesting data is that, activation of senescence correlated with a better prognosis 
following chemiotehrapy [55]. These experimental evidences suggest that 
senescence can improve the effectiveness of chemotherapeutic treatment [2]. Of 
note, two reports analysing senescence markers in biopsies from patients with 
lung or breast cancer after neoadjuvant chemotherapy have observed 
chemotherapy-induced senescence and its association with treatment success 
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[54,56]. More recently, the analysis of biopsy material from patients with prostate 
cancer has shown that chemotherapy induces marker of senescence [30].  
Although are actually in developing several strategies to induce the activation of 
senescence, it must bear in mind the potential problems that might arise from 
senescence-induced therapies.  One of the most important problems is that, cancer 
cells in a senescence-like state might remain as „dormant‟ tumour cells and 
therefore represent  a dangerous potential for tumour relapses [2].  
For this reason, the therapeutical protocols based on the use of molecules that 
induce senescence might induce at the same times the activation of processes 
which are responsible to eliminate senescence cells.  
Senescent cells can secrete molecules and factors, such as IL-6 and IL-8, which 
are responsible to recruit immune cells (such as neutrophils, macrophages and 
natural killer cells) to sites of senescence and to clearance it [73]. Thus, these data 
suggest to promoting immune cell function, while also engaging a pro-senescence 
response, may prove to be beneficial for the clearance of senescence cells and 
may result in tumour regression.  In virtù del ruolo svolto dalle cellule del sistema 
immunitario, è chiaro che potenziarne l‟azione è sicuramente di fondamentale 
importanza nel potenziare il fenomeno della regressione tumorale.  
SASP component, such as interleukin, might then have an important role in 
sustaining senescence activation and tumour clearance, but it is important to bear 
in mind that some SASP molecules might also stimulate the malignant phenotype 
of nearby tumour cells [30].  
Before introducing the use of  induced senescence for therapeutic purposes, it will 
be therefore necessary to complete studies considering also the side effects that 
are generated by such a process. 
 
1.2. mTOR 
mTOR (mammalian target of rapamycin) is a serine/threonine kinase which 
regulates protein synthesis, cell growth and proliferation in response to pleiotropic 
inputs including growth factors, nutrients, stress and energy [74].  
It was identified in the yeast Saccharomyces Cerevisiae during a screen for 
resistance to the immunosuppressant drug rapamycin [75, 76].  
mTOR is a member of the phosphoinositide 3-kinase (PIKK) family, whose 
catalytic domain has omology to that of PI3Ks [77].  
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Unlike PI3K family member which phosphorylate lipids, the PIKK (ATM; ATR, 
DNA-PKcs, mTOR, SMG1 e TRRAP) act as serine/threonine kinases [78]. 
mTOR is a central signalling molecule, than it is implicated in various syndrome 
and hamartoma syndromes [79]. There are several hamartoma syndromes which 
are caused by mutations or deregulation of mTOR pathway, such as TSC1-TSC2 
(Tuberous Sclerosis Complex )[81, 82], NF1 (Neurofibromatosis Type I) [82], 
LKB1 (Peutz-Jeghers Syndrome ) [84], PTEN (Cowden disease) [84,85] e FLCN 
(Birt-Hogg-Dubé sindrome) [86-88].  
mTOR is a high molecular weight proteins (280Kda) that contains several 
structural domains. The N-terminus posses 20 HEAT repeats that are implicated 
in protein-protein interactions. The C-terminus contains the kinase domain, which 
has sequence similarity with PI3K. Upstream to the catalytic domain are present 
the FRB domain responsible to the interaction with rapamycin. Furthermore, 
upstream to FRB domain there is the FAT domain, typical of PIKK kinases. 
Finally in the C-terminus region is present the FATC domain, that is necessary  
for mTOR activity, in fact deletion or even single base mutations abrogates the 
activity of mTOR [89]. 
In mamamlial mTOR formed two distinct complexes, called respectively 
mTORC1 and mTORC2 (Fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
Fig.5: Domain organization of mTOR and mTORc proteins [90] 
 
mTORC1 is a rapamycin-sensible complex. Rapamycin was originally isolated 
from the bacterium Streptomyces Hygroscopicus, inhibits proliferation of 
mammalial cells and possess immunosuppressive properties [74]. Rapamycin in 
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cells binds the protein FKBP12 (FK506-binfìding protein), then the complex 
rapamycin-FKBP12 binds and inhibits raptor-bind to mTOR, instead do not have 
effect on rictor [91]. Prolonged treatment with rapamycin can inhibits mTORC2 
in some tissues and cell lines. This effect may be due to the sequestration of the 
pool of mTOR in the complex rapamycin-FKBP12 [92].  
The subunits that composed mTORC1 are: mTOR, RAPTOR (Regulatory 
associated protein of mTOR), PRAS40, GβLe DEPTOR. RAPTOR acts as an 
adaptator subunit and is important to recruit substrates to mTOR, PRAS40 e 
DEPTOR are negative regulators of mTORC1 complex, instead GβL is a positive 
regulator of the complex [74,90]. 
mTORC2 complex is composed by the following subunits, some of which are 
common to mTORC1: mTOR, RICTOR, PROTOR, DEPTOR, GβL e mSIN1. 
RICTOR, as well as RAPTOR, acts as a scaffold; PROTOR regulates complex 
assembly, instead mSIN1 target mTORC2 to membranes [90].  
mTORC1 and mTORC2 are responsible to regulate different processes: mTORC1 
is responsible to regulate protein synthesis, proliferation and cellular growth. 
mTORC2 regulates proliferation and actin reorganization [90]. 
mTORC1 promotes cell growth through phosphorylation of various regulators of 
translation, including the well-characterized ribosomal S6K1, which activates the 
S6 ribosomal protein (S6), and the eukaryotic translation initiation factor 4E-
binding protein1 (4EBP1), which leads to its uncoupling from the elongation 
initiation factorE (eiF4e) [74]. 
S6K1 and 4EBP1 associate with mRNAs and regulate mRNA translation 
initiation and progression, thus controlling the rate of protein synthesis. 
Unphosphorylated 4E-BP1 suppresses mRNA translation: however when 
phosphorylated by mTORC1, 4E-BP1 dissociates from eIF4E allowing eIF4E to 
recruit the translation initiation factor eIF4G to the 5‟ end of most mRNAs [90]. 
When phosphorylated by mTORC1 S6K1 promotes mRNA translation by 
phosphorylating or binding multiple proteins, including eukaryotic elongation 
factor 2 kinase (eIF2K), S6K1 Aly/REF-like target (SKAR), 80kDa nuclear cap-
binding protein (CBP80) and eIF4B, which collectively affect translation 
initiation and elongation [90]. eIF4B is responsible to enhances the activity of 
eIF4A, an RNA helicase that unwind the structured 5‟UTR of many mRNAs [90].  
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Moreover, studies in yeast S.Cerevisae demonstrated that mTORC1 suppress 
autophagy [93,94].  
Recently, several experimental data have demonstrated that mTORC1 is involved 
in the regulation of cellular senescence. In a recent report, the persistent 
expression of Wnt proteins in mouse epiderms led to hyperproliferation of 
epithelial stem cells, ultimately causing them to undergo senescence. These action 
seemed to occur through Wnt-mediated activation of mTOR pathway [95]. 
The involvement of mTOR in the regulation of cellular senescence it has been 
shown even in PICS; where it was shown that p53 up-regulation is caused by 
mTOR-mediated translation consequent to the loss of PTEN [46,47].  
Recently it has been shown in fibroblast that PI3K/AKT pathway activation in 
response to PTEN knockdown, mutant PI3K or activated AKT expression, 
induces cellular senescence. It was demonstrated that AKT-induced senescence 
senescence is p53-dependent, and that mTORC1 have a pivotal role in regulation 
p53 translation and stabilization of p53 protein following nucleolar localisation 
and inactivation of MDM2 [96].   
mTORC1 acts as a signal integrator  for four major regulatory inputs: growth 
factors, nutrients, energy and stress [90].  
mTOR responds to growth factors via the PI3K/AKT pathway [74, 90]. Binding 
of insuline to its receptor activates the PI3K pathway, which converts PIP2 
(phosphatidiylinositol-4,5-phosphate) in PIP3. PIP3 accumulation is antagonized 
by the tumor suppressor gene PTEN. PIP3 recruits PDK1 and AKT to the 
membrane, resulting in the phosphorylation and activation of AKT by PDK1.   
When AKT is activated, phosphorylates and inactivates TSC1 and TSC2 and, 
consequently, activates mTORC1 [97-99]. In fact, TSC1 and TSC2 form a 
complex which have been shown to negatively regulate mTORC1 [105]. TSC2 
was shown to have a GTPase activating protein (GAP) activity towards the Rheb 
(ras-homolog enriched in brain) GTPase; this event stimulates the intrinsic GTP 
hydrolysis activity of Rheb to promote its transition from an active GTP-bound 
form to an inactive GDP-bound form [100]. 
Conversely inactivation of TSC1/TSC2 by AKT phosphorylation lead to GTP 
binding and Rheb activation which ultimately promotes the activation of 
mTORC1. 
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AKT also phosphorylates PRAS40 a component of mTORC1, which causes it to 
bind to 14-3-3 proteins and prevents it from inhibiting mTORC1 [101]. 
mTORC1 senses also cellular energy [90]. The mTORC1 pathway indirectly 
senses low ATP by a mechanism that involved the AMPK kinase. Both AMP and 
ATP are allosteric regulators of AMPK, when the AMP:ATP ratio increases, 
AMPK phosphorylates TSC2, therefore the GAP activity of TSC1-TSC2 towards 
Rheb is stimulating, and the mTORC1 signaling is inhibited [90]. Moreover 
AMPK phosphorylates Raptor, causing it to bind to 14-3-3 proteins, which lead to 
mTORC1 inhibition [101]. Other stressor that not primarly impinge on cellular 
energy can inhibit mTORC1 through the involvement of AMPK. For example, 
DNA damage result in inhibition of mTORC1 activity through the p53-dependent  
upregulation of AMPK [102, 103]. Sestrin1 and 2 are two transcriptional targets 
of p53  that are impliocated in the DNA damage response, and it was recently 
shown that sestrin potently activate AMPK, thus mediating the p53-dependent 
suppression of mTOR activity upon DNA damage [104]  
 
1.3 MITOCHONDRIA 
Mitochondria are cytoplasmic organell present in every eukaryotic cells, animal or 
vegetal with an aerobic metabolism. Mitochondria are the main producers of 
energy in a cell [106, 107], but they are involved in other metabolic processes, 
such as Krebs cycle, pyruvate and fatty acid oxidation, nitrogen metabolism and 
heme metabolism [108, 109]. Moreover, mitochondria are involved in calcium 
homeostasis maintenance, production and regulation of reactive oxygen species 
(ROS) and in the regulation of apoptosis [106, 107, 108]. Mitochondria are 
endowed with a two-membrane system in which the outer and the inner 
membrane differ in lipoprotein content and permeability and thus create two 
separate sub-compartments; the intermembrane space and the inner matrix, each 
hosting different metabolic reactions and molecular processes. The outer 
mitochondrial membrane is more permeable, mainly due to the voltage dependent 
anion channel (VDAC) known as porin [110], while the inner membrane is almost 
completely impermeable, particularly for protons, which allows the formation of 
the proton gradient crucial for the mitochondrial energy production. The low 
permeability of inner membrane is attributed to the absence of porin and to the 
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elevate presence of cardiolipin, a phospholipid which modulates the activities of 
some respiratory chain enzyme [111].  
The surface of the inner membrane folds into tubular formations called christae 
(Fig.6) which protrude in the matrix and increasing the surface of energy 
production. In the christae are located almost all the protein that constitute the 
electron transport chain. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6: Mitochondrial structure [112] 
  
Mitochondria are the main producers of energy in a cell; through the process 
called oxidative phosphorylation, protein complexes of the electron transport 
chain (CI, CII, CIII and CIV) and ATP synthase (CV), situated in the inner 
mitochondrial membrane, utilize hydrogen to reduce oxygen into water and 
generate ATP (Fig. 7).  
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Fig.7: Protein subunits of the five respiratory complexes encoded by nuclear and mitochondrial 
genes. [109]
 
 
              1.3.1 Mitochondrial genome 
Mitochondria are unique among eukaryotic organelles in that they contain their 
own genetic system. Only a small number of genes necessary to account for the 
molecular architecture and biological function of the organelle are present in 
mtDNA. Because of this limited coding capacity, mitochondrial are genetically 
semi-autonumous, in fact they rely on the expression of nuclear genes for all of 
their biological function [109]. For example, the majority of subunits that 
comprise the complexes of electron transport chain, and the enzyme involved in 
replication and transcription are nucleus encoded.  
Human mtDNA is a double-stranded molecules that consists of 16569 bp 
113,114,115] is located in mitochondrial matrix and carries genes encoding for 13 
subunits of electron transport chain complexes, as well as 2 rRNAs and 22 tRNAs 
(Fig. 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.8:  Schematic representation of the human mitochondrial genome 
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mtDNA has some characterists that are different from those of the nuclear genome 
(nDNA). The genetic information of mtDNA is extremely compacted, 
mitochondrial genes lack introns and there are little or no intergenic regions. 
Some respiratory protein genes overlap and finally, another characteristic of 
mtDNA is the use of mitochondria specific codons, which differ from the 
universal genetic code [116].  
Although mitochondria do not contain introns, recent discoveries showed that 
mtDNA is actually protein-coated and packed in aggregates called mitochondrial 
nucleoids, together with the machinery necessary for its replication and 
transcription  [117, 118] such as POLG (mtDNA polymerase gamma) or TFAM 
(mitochondrial transcription factor) to which a role in mtDNA packaging and 
organization has recently been assigned [118-120].  
The only non coding regions in mtDNA is the D-loop (displacement loop), a 
control region which contains replication and transcription factor binding sites.  
Mitochondrial genome is inherited maternally, in fact only mitochondria from the 
oocyte contribute to gamete development, while sperm mtDNA tends to be 
eliminated via proteosoma after fertilization through their ubiquitination in 
spermatogonia [121-123].  
Mammalial cell generally have many mitochondria, each of them carries several 
(2-10) mtDNA molecules [124], that are not always genetically uniform. The 
coexistence of both mutated and wild type mtDNA in a cell is a condition called 
heteroplasmia. On the other hand, homoplasmy is a condition typical of a cell that 
present only one mtDNA genotype [124]. A direct consequence of polyploidia 
and heteroplasmy is the threshold effect. The phenotypic effect of a mtDNA 
mutation depends on the percentage of its mutant load. The portion of mutated 
molecules needs to be reached before the functional consequences of a mtDNA 
mutation begin to arise, depending on the type of the mutation and on the tissue in 
which it occurred. In fact, tissue that have an elevated oxidative metabolism, such 
as brain, skeletale muscle and heart, have a low threshold with respect to other 
tissue.    
 
1.3.2 Mitochondrial biogenesis 
The energetic demands can vary substantially between different cell types and in 
different physiological situations requiring an adaptation in mitochondrial 
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biogenesis, which is a complex phenomenon that needs the participation and 
coordination of nuclear and mitochondrial genomes [109]. Many activators and 
coactivators are involved in the coordinated upregulation of nuclear and 
mitochondrial genes that are necessary for an efficient mitochondrial biogenesis 
(for example nuclear genes encoding respiratory subunits, mitochondrial 
transcription and replication factors, heme biosynthetic enzymes, protein import 
machinery). 
Physiological signals may activate specific transcription factors through different 
pathways and this can result in an activation of genes required for mitochondrial 
biogenesis and respiratory function. The nuclear transcriptional factors involved 
in regulating mitochondrial biogenesis are: Nuclear Respiratory Factors 1 and 2 
(NRF-1 and NRF-2), YY1 and CREB. They act on the majority of nuclear genes 
encoding subunits of the respiratory chain complexes [109], and are also involved 
in the expression of mitochondrial transcription and replication factors (TFAM, 
TFB1M and TFB2M), heme biosynthetic enzymes and other proteins required for 
respiratory function [125, 127].  
In addition to these transcription factors, mitochondrial biogenesis is controlled by 
transcriptional coactivators, such as PGC-1α (PPARγ coactivator-1), PGC-1β and 
PRC, which interact with other transcription factors and coactivators  [126]. 
PGC-1α is the main regulator of mitochondrial biogenesis in mammalial cells. It 
was identified in brown fat tissue (BAT), through its interaction with PPARγ 
(Peroxisome Proliferators-Activated Receptor γ), a regulator of adipocyte 
differentiation [109]. It is expressed at high levels in tissues where mitochondria 
are abundant, such as brown adipose tissue (BAT), heart and skeletal muscle. 
Instead, the expression level is low in tissues such as liver and white adipose 
tissue [131]. 
PGC-1α can induce mitochondrial biogenesis by interaction with several 
transcription factors, such as NRF-1, NRF-2, ERRα and YY1 [109].  
Recently it was shown that AMPK kinase, a key regulator of cellular energy 
homeostasis, is the mainly regulator of mitochondrial biogenesis upon energy 
depletion through inhibition of PGC-1α activity[129, 130]. In condition of energy 
depletion, AMPK is activated and is responsible to phosphorylates PGC-1α on 
specific serine and threonine residues. This results in increased mitochondrial 
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gene expression and activation of ATP production; instead all the molecular 
pathways that use ATP are inhibited.  
More recently, it has been demonstrated that PGC-1α gene expression is regulated 
by mTORC1 [132]. In skeletal muscle it has been demonstrated that 
pharmacological inhibition of mTORC1 is responsible to decreased PGC-1α 
expression and of some of its interactors such as NRF-1, NRF-2 and ERR-α. The 
result is a decrease in mitochondrial biogenesis, even as proteins expression than 
in terms of oxygen consumption [132]. It has also been demonstrated that 
mTORC1 and PGC-1α interact with YY1 (Ying-Yang 1), which seems directly 
bind mitochondrial gene promoters. mTORC1 were shown to directly interact 
with YY1 and PGC-1α, and mTORC1 was demonstrated to regulate the 
transcriptional function of YY1-PGC-1α by altering their physical interaction 
[132].  
In another study it has been demonstrated that mTOR and raptor can be purified in 
mitochondrial fraction; moreover pharmacological inhibition of mTORC1 through 
rapamycin, resulted in a marked alteration of mitochondrial transcriptoma [133].  
 
1.3.3 Oncocytic tumors: a model to study mitochondrial dysfunction 
Oncocytic tumors are an interesting model to study the effect of mitochondrial 
dysfunction on cancer development. Oncocytic tumors may arise in different 
types of tissues, most often in those of epithelial origin such as thyroid, kidney or 
pituitary gland [134].  
They are characterized by an aberrant mitochondrial hyperplasia, that is 
responsible for their “swollen” appearance [135]. This feature can be appreciated 
through ultrastructural analysis, which displays cells packed with enlarged 
globular or ovate mitochondria with a stack of lamelliform, tubular or flat cristae 
and occupying up to 60% of the cytoplasm [134, 136, 137].  
The majority of oncocytic neoplasms is considered benign and display low-
proliferating, non-invasive behaviour [134, 135, 138-144]. Moreover, a strong 
association between complex I disruption and HIF-1 α (Hypoxia inducible factor 
1) destabilization has been shown. The mitochondrial mutation lead to an increase 
of α-chetoglutarate/succinate ratio, which may be responsible for a higher 
affinity/activity of the prolyl hydroxylase (PHD) responsible to mediate HIF-1α 
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degradation. Such metabolic switch was suggested to explain why onocytic 
tumors might excape malignancy [144].  
The mitochondrial hyperplasia is caused by a compensatory effect as a 
consequence of a respiratory dysfunction triggered in presence of a retrograde 
signalling from the organelles to the nucleus [135]. This stress response can be 
activated in response to several kinds of stimuli, such as loss of mitochondrial 
function caused by collapse of electrochemical potential , impaired respiratory 
chain activity or by the accumulation of unfolded proteins in the organelle [135].   
Several studies have investigated the increase in mitochondrial biogenesis in 
oncocytic tumors as well as in the only existing oncocytic model, the XTC.UC1 
cell line [135]. The group of Prof. Romeo fully characterized the bioenergetic 
competence of  XTC.UC1. It has been shown that the energetic impairment is due 
to a decrease in both complex I and complex III activity due to the presence of 
mtDNA mutations respectively in ND1 and cytocrome b [142]. A similar decrease 
in complex I subunits content was reported in a case of a rare nasopharynx 
oncocytoma, along with a mtDNA copy number ncrease [140]. Instead, decrease 
in activity of complex I and IV was reported in vivo in a peculiar case of Warthin 
tumor [144].  
All these data point at a dysfunction at least in respiratory complex I as the main 
trigger for the subsequent increase in other mitochondrial proteins and, hence, for 
the compensatory effect in oncocytic cells [135]. 
However how mtDNA mutations contributes to oncocytic development is not so 
clear. It is worth noting that the mtDNA mutations underlying the oncocytic 
phenotype may not be the primary hit in tumorigenesis as previously discuss 
[141].  The hypothesis of the active contribution of the mtDNA mutation to the 
oncocytic transformation fits well with the model of the compensatory effect. In 
fact, based on this model, the mtDNA mutation may cause the respiratory 
dysfunction which triggers a retrograde signalking to the nucleus resulting in 
mitochondrial biogenesis [135].  
 
1.4 COWDEN SYNDROME AND PTEN 
Cowden Syndrome (CS) belongs to the family of the PTEN hamartoma tumor 
syndromes (PHTS) that also includes Bannayan-Riley-Ruvalcaba syndrome 
(BRRS), Proteus syndrome (PS) and Proteus like syndrome [145].  
 27 
CS is a highly variable, autosomal-dominant hereditary cancer susceptibility 
syndrome. The patients affected by CS developed multiple hamartomas, unusual 
skin and facial findings, abnormal CNS findings and increased risk of 
malignancies.  
Mutations in the tumor suppressor gene PTEN (Phosphatase and Tensin 
homologue on chromosome 10) are the cause of CS [146].   
The majority of mutations occur in exon 5, but mutations in the other exons, 
except for the first, have also been reported. CS patients are characterized by  
germ-line mutations of PTEN including nonsense, frameshift, splice site, missense 
mutations, as well as deletion/insertion of one or more exons all leading to 
monoallelic loss of function.  
PTEN is a “haplo-insufficient” tumor suppressor gene, which is particularly 
sensitive to dosage. Generally, tumor suppressor genes must be fully inactivated 
to participate in tumor initiation and progression, as explained by Knudson‟s 
“two-hit Hypothesis”. It has been shown in some cases, that many deleted regions 
in a tumor or in patients are not accompanied by mutations or deletion of the other 
allele. This suggests that these deletions could be passenger events, not implied in 
tumorigenesis. The alternative explanation is that the deleted region includes 
tumor suppressor genes for which the loss of one single copy has a role in 
tumorigenesis. Another hypothesis is that the single mutation acts as a dominant 
negative towards the other allele resulting in loss of both copies function, 
mimicking the effect of homozygous or, third hypothesis, both copies of the gene 
are necessary to maintain its function. In this case a single-copy loss of function 
mutation may be sufficient to cause the phenotype. 
PTEN dosage-dependence was first demonstrated in mice [183] in which loss of 
one allele of PTEN has been shown to promote the progression of a lethal 
polyclonal autoimmune disorder with high penetrance. These findings suggested 
that a residual wild type allele is not enough to sustain normal function. Similarly 
PTEN heterozygosity appeared to promote epithelial cancers, such as prostate 
cancer, in mouse model of PTEN loss [184]. 
 
1.4.1 PTEN: Structure and functions. 
The PTEN (Phosphatase and tensin homologue deleted in chromosome 10) tumor-
suppressor gene is located on chromosome 10q23.3, a genomic region that suffers 
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loss of heterozygosisty (LOH) in many human cancers [147]. Somatic deletion or 
mutations of this gene have been identified in a large fraction of tumors, including 
glioblastomas, endometrial and advanced prostate cancer, thus placing PTEN 
among the most commonly mutated genes in human cancer [148]. 
PTEN encodes for a dual protein/ lipid phosphatase. There are two major domains 
of PTEN, the N-terminal phosphatase domain and the C-terminal domain. Tumor 
suppressor function requires both the phosphatase domain and the C2 or lipid 
membrane binding domain. The PZD domain is responsible to the interaction with 
other proteins, instead the PEST domain may contribute to protein stability (Fig. 
9).  
 
 
 
 
 
Fig. 9: PTEN domains structure  
 
PTEN primary target is the phosphatydil-inositol 3,4,5 triphosphate (PPI3) which 
is the direct product of the phosphatidylinositol 3-kinase (PI3K). Loss of PTEN 
function, either in murine embryonic stem cells or in human cancer cell lines, 
results in accumulation of PIP3 mimicking the effect of PI3K activation and 
triggering the activation of its downstream effectors, PDK1, AKT/PKB and 
Rac1/cdc42. Activated PDK1 phosphorylates AKT at Thr308 activating its serine-
threonine kinase activity. 
Once phosphorylated in Thr308, further activation occurs by PDK2 (mTORC2 or 
DNA-PK) by phosphorylation at Ser473. AKT activation stimulates cell cycle 
progression, survival, metabolism and migration through phosphorylation of many 
physiological substrates [150]. 
PTEN therefore negatively regulates the AKT pathway leading to decreased 
phosphorylation of AKT substrates such as TSC2 and PRAS40 that control 
mTOR activity, p27, p21, glycone synthase kinase 3 (GSK3A), BCL-2-associated 
agonist cell death (BAD), apoptosis signal regulating kinase 1 (MPK3K5), WT1 
regulator PAWR (also known as PAR 4) and CHK1, as well as members of the 
fork-head transcription factor family (for example FOXO1, FOXO3 and FOXO4) 
and others. 
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Changes in phosphorylation alter the activity and/or localization of these proteins, 
which in turn affects processes such as cell cycle progression, metabolism, 
migration, apoptosis, transcription and translation (Fig.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.10: The PTEN-PI3K Pathway. 
 
PTEN phosphatase also targets different proteins, including proteins that regulate 
cell migration and invasion, such as p130 and FAK, and pathways that control 
proliferation and differentiation, such as MAPK.  
It has recently demonstrated that PTEN have a nuclear function [151,152]. It is 
important to notice that PTEN does not contain typical nuclear localization signals 
(NLS) or nuclear export motifs (NES). Several mechanisms for the nucleus-
cytoplasmic shuttling of PTEN have been postulated, including simple diffusion; 
export dependent on a putative cytoplasmic localization signal, active shuttling by 
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the RAN-GTPase or major vault protein (MVP), phosphorylation dependent 
shuttling and monoubiquitylation-dependent import [151]. 
 It has been shown that nuclear PTEN acts to maintain chromosomal stability 
[152]. The binding of PTEN to centromere protein C1 (CENP-C1) is required for 
centromere stability, and its nuclear localization is required for DNA double-
strand breaks (DBS) repair that is mediated by DNA repair protein RAD51. PTEN 
also regulates the tumor suppressor function of anaphase-promoting complex 
(APC) and of its regulator E-cadherin, in the nucleus, independently of its lipid 
phosphatase activity. Altered APC-CDH1 activity has been implicated in multiple 
tumor types. 
Furthermore in vitro studies demonstrated that nuclear PTEN induces G0-G1 
arrest since cells expressing wild type PTEN protein exhibit a slower growth rate 
and higher G1:S ratio than cells expressing the nuclear-localization-defective 
mutant. This increase in the number of cells in G0-G1 is probably a direct result 
of down regulation of cyclin D1 by nuclear PTEN. It might lead to decreased 
tumor growth, explaining another aspect of PTEN tumor-suppressor function [50]. 
 
1.5 BIRT-HOGG-DUBE’ SYNDROME AND FLCN 
Birt-Hogg-Dube syndrome (BHD) is an autosomal dominant condition, caused by 
germline mutations in the FLCN (folliculin) gene. Patients affected by this 
syndrome are characterised by skin fibrofolliculomas, multiple lung cysts, 
spontaneous pneumothorax, and renal cancer [153].   
 
1.5.1 FLCN: structure and functions 
FLCN is located on chromosome 17p11.2; and it consists of 14 exons [153]. 
The majority of mutations, identified in FLCN sequence, were predicted to 
introduce a premature stop codon into FLCN and therefore to result in protein 
truncation [154]. This includes the “hot spot” for insertions/deletions in exon 11.  
It is unclear whether the truncated FLCN is targeted for degradation or remains in 
the cell with an altered function 
Somatic mutations in the remaining wild type  allele of FLCN or loss of 
heterozygosity on chromosome 17p11.2 have been identified in BHD-associated 
renal tumors, supporting Knudson “two-hit” hypothesis and a tumor suppressor 
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role for FLCN [80]. However there is evidence that FLCN does not behave as 
typical tumor suppressor protein. 
In a study of five BHD patients [81] the authors found no evidence of somatic 
mutations and loss of heterozigosity in fibrofolliculomas suggesting that 
haploinsufficiency is enough to cause benign tumor growth in the skin. 
FLCN consisting of a short hydrophobic N-terminal sequence, one N-
glycosylation site, three myristoylation sites and a glutamic-acid rich coiled coil 
domain centrally located in the protein [154].  
Two FLCN-interacting proteins have been described: FNIP1 and FNIP2. FLCN-
binding protein 1 (FNIP1) was identified in 2006 [155] as an evolutionary 
conserved protein that interacts with and phosphorylates FLCN. 
FNIP1 also binds AMPK, which is a negative regulator of mTOR and a key 
protein for energy sensing in cells [155,156] demonstrated that both FLCN and 
FNIP1 are phosphorylated by AMPK. This interaction between FNIP1 and FLCN 
was also shown to be modified by external influences, since treatment with an 
AMPK inhibitor (compound C), rapamycin or amino acid starvation affected the 
phosphorylation status of FLCN, further indicating a role for FLCN in energy 
sensing and the mTOR pathway.  
FNIP2, is a second FLCN-binding protein and it is homologous to FNIP1 (49% 
identity, 74% similarity). As with FNIP1, it is conserved across species and binds 
AMPK [157,158] in vitro kinase assays also suggest that FNIP2 is phosphorylated 
by AMPK [158]. FNIP1 and FNIP2 are able to form homo- and heterodimers, as 
well as multimers [158] suggesting a functional association between these two 
proteins. 
Further research has shown that Ser 62 is a phosphorylation site in FLCN, this 
work also suggests that ser62 phosphorylation is indirectly up-regulated by 
AMPK [159]. FLCN also appears to be phosphorylated at Ser302 by unknown 
kinases downstream of mTORC1 [160].  Since mTORC1 is known to be 
indirectly down-regulated by AMPK, this process could be associated with an 
unknown feedback mechanism that regulates mTOR signaling.  
The molecular functions of FLCN are poorly understood, but it is known that 
FLCN and AMPK interaction, as mediated by FNIP1 and FNIP2, is involved in 
mTOR signaling [155].  
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Nevertheless the functional role of FLCN in mTOR signaling is undetermined, 
since several recent publications have reported contradictory effects on an 
indicator of mTOR activation (known as phosphorylated ribosomal protein S6 / p-
S6R) when FLCN expression is reduced. Two studies recently reported that 
transient downregulation of FLCN by siRNA in human cell lines results in 
reduction of phosphorylation of p-S6R [158, 161]. Reduction of p-S6R was also 
observed in renal cysts developing in mice heterozygous for FLCN [162]. In 
contrast, kidney-specific homozygous knockout of FLCN resulted in an increase 
in phosphorylated p-S6R, which contributed to the development of polycystic 
kidneys [163].  
Recent research has also indicated a role for FLCN in other signaling systems and 
cellular processes (Fig.11). 
 
 
 
 
 
 
 
 
 
 
 
Fig.11: FLCN pathway and interactors. 
 
Other cellular pathways seem to be controlled by FLCN function; using a RCC 
cell line derived from a BHD patient [164] demonstrated that FLCN also 
influences HIF-1α signaling. The authors suggested that a high level of HIF-
mediated expression in these FLCN-null cells alters cell metabolism through 
elevated levels of metabolic enzymes. This altered metabolic state parallels a 
phenomenon known as the Warburg effect, which is commonly seen in cancerous 
cells [165] postulated that cancer should in fact be interpreted as a mitochondrial 
disease, and further work [166] suggests that the loss of FLCN in BHD syndrome 
results in mitochondrial dysfunction, as indicated by a high level of mitochondrial 
gene expression. 
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2.MATERIALS AND METHODS 
 
 
Cell lines  
The following cell line was utilized for the study: 
- RPE1: ephitelial cell line derived from human retina with non-rearranged 
cariotype 
-  XTC.UC1 (Thyroid Oncocytoma Cell Line): cell line derived from an oncocytic 
thyroid tumor [Zielke A et al., 1998]. 
- HCT116: human cell line derived from a colon-rectal tumor 
- HEK293: an immortalized cell line derived from human embryonic kidney 
- HPS11: ci-hybrid cell line derived from the fusion of fibroblast enucleated from 
a health patient and, as cytoplasmic donors the 143B TK
-
 deprived of their 
mtDNA (Rho0) [G.Attardi e M.King, 1989] 
 
RPE1 and XTC.UC1 were cultured in DF12 medium (Dulbecco‟s modified 
eagle‟s medium/nutrient mixture F-12 ham (Sigma)) supplemented with 10% fetal 
bovine serum (FBS) and  1% penicillin G-streptomycin.  
HCT116, HEK293 and HPS11 were cultured in DMEM (Dulbecco’s Modified 
Eagle Medium) supplemented with 10% FBS, 1% penicillin G-streptomycina and 
1% L-glutammine. 
Cells  were maintained in 5% C02 at 37°C 
 
 γ-rays treatment 
For γ-rays treatment is followed a standard protocol, previously optimized in our 
laboratory. The biological irradiator IBL437C (89-294) is used for the treatment. 
Cell are growth in T25 flaks, and the treatment is started the day after the seeding. 
Each cell lines is irradiated at 4Gy for 3/4 days as indicated in Table 1.  
 
 
 
  RPE1 
T0 Untreated control 
IR4 4 doses of 4 Gy 
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RL 4 doses of 4 Gy and 120 hours of recovery  
 
  XTC.UC1 
T0 Untreated control 
IR4 4 doses of 4 Gy 
RL 4 doses of 4 Gy and 120 hours of recovery 
 
  HCT116 
T0 Untreated control 
IR3 3 doses of 4 Gy 
RL 3 doses of 4 Gy and 120 hours of recovery  
 
Rapamycin treatment 
Cells are treated with rapamycin (Cell Signaling), a specific inhibitor of mTORC1 
complex. Rapamycin is a bacterial macrolide with antifungal and 
immunosuppressive activity. Rapamycin forms a complex with the immuniphilin 
FKBP12 which then inhibits the activity of mTORC1. The treatment leads to the 
desphosphorylation and inactivation of p70S6K kinase.    
Cells are seeded in T25 cm
2
 flasks, the day after the culture medium was replaced 
with medium containing rapamycin 10nM (optimal dose that induces 
dephosphorylation of p70S6K).  
For each cell lines a flask was subjected to a combined treatment 
rapamycin+radiation. The time and doses of irradiation are the same indicated in 
table 1. After the last dose of radiation, the medium is substituted with fresh 
medium containing rapamycin. After 120h of recovery the cells are utilized for 
the successive analysis. 
SA-β-Gal assay 
The marker that is commonly used to identify senescent cells is Senescence-
Associated β-galactosidase activity (SA-βgal) [26]. In normal cells, β-
galactosidase, a lysosomal enzyme, is active at pH 4; instead senescent cells are 
characterized by an increase activity of this enzyme. Consequently, the β-
galactosidase activity can be measured also at suboptimal pH6.  
For the assay, cells are seeded in T25 cm
2
 flasks, washed twice with PBS and then 
incubated with a fixing solution for 7‟ at RT. This solution contains: 
- Glutaraldeide 2% 
- Formaldeid 0.2% 
- PBS 
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Then the flasks are washed five times with PBS and then incubated with a staining 
solution. The staining solution contains: 
- Citric acid+Sodium Phosphate Buffer 40mM at pH 6 
- K4[Fe(CN)6]x3H2O 5mM 
- K3[Fe(CN)6] 5mM 
- NaCl 150mM 
- MgCl2 1mM 
- X-Gal 1mg/ml 
- H2O 
The flasks are incubated at 37°C (without CO2) and protected from light. 
The day after the staining solution is eliminated and the flasks washed twice with 
PBS and then microphotographeted.    
Flow cytometry 
In order to confirm the proliferative arrest induced in a senescent cell, the 
distribution of cells in the different phases of cell cycle was analized. 
The protocol derive from the original Nusse protocol (Nusse, M., et al “Flow 
citometric analysis of G1- and G2/M phase subpopulations in mammalial cell 
nuclei using side scatter and DNA contenent measurements” . Cytometry 11: 813-
821 (1990)). 
Cells are seeded at low confluence and subjected to γ-rays treatment as indicated 
in table 1.  
At the end of the treatment, cells are first pelletted at 1500rpm for 10‟, then are 
resuspended with Nusse 1 Solution at a final concentration of 2x10
6
 cells/mL. The 
Nusse 1 Solution contains: 
- NaCl 584mg/L 
- Trisodic Citrate 1139 mg/L 
- RNAsi 10mg/L 
- Nonidet P40 300 μg/L 
- H2O 
Cells are incubated for 30‟/1h in ice. Then is added Nusse 2 Solution (same 
volume of Nusse 1 Solution) to reach a final concentration of 1x10
6
cells/mL. The 
solution is vortexed and the sample is transferred in a cytoflurimetric tube and 
incubated with Propidium Iodide (50μg/mL) for 15‟ and then analysed with a flow 
cytometer (BD-FACSAria). 
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DCDFA 
To evaluate the hydrogen peroxide production, cells are incubated with 
dichlorodihydrofluorescein diacetate (DCFDA) as indicated by manufacturer. 
Cells were seeded in dishes (60mm
3
) and irradiated following the protocol 
optimized for each cell lines. After 120h of recovery in incubator, cells were 
washed twice with PBS, then is added DMEM without red-phenol and cells are 
incubated for 30‟ at 37°C with 2μM of DCDFA. At the end of the incubation, 
cells is washed twice with PBS, fresh DMEM without red-phenol is added  and 
then the dishes is analyzed at immunofluorescent microscope. 
Cloning 
PTEN and FLCN complete cDNA were cloned in two different plasmid vectors, 
respectively pcDNA 3.1(-)PURO and pcDNA 3.1(+)ZEO.  
The pcDNA 3.1(-)PURO plasmid derived from pcDNA3.1 NEO (Invitrogen), and 
carries a puromycin resistant casset, for selection in mammalial cells, which 
substitues the neomycin cassette of the original vector.  
For PTEN cloning are used the following primers: 
PTEN-EcoRI-FW CGGAATTCGCCACCTGACAGCCATCATC  
PTEN-HindIII-RV GACAAGCTTTCAGATTTTGTAATTG 
The reaction is prepared as indicated:  
- cDNA 1 μl 
- BUFFER 10X 2 μl 
- dNTPs (2mM) 2 μl 
- MgCl2  1,6 μl 
- PRIMER FW+RV 2+2 μl 
- Fast Taq (Roche) 0.2 μl 
- H2O 9,2 μl 
And the theromcycler impostated as indicated: 
 
Temperature Time Cycle 
96°C 10 min 1 
96°C 30 sec  
30 60°C 30 sec 
72°C 30 sec 
72°C 7 min 1 
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The PCR product is then cloned in pGEM-T Easy vector system (Promega) for 
the amplification. First the polyA is added at the PCR product by the addiction of 
0,2μl of Taq Gold (Invitrogen) and the mixture incubated 15min at 72°C. Then, 
the transformation reaction is prepared as following indicated: 
- PCR 1,5μl 
- pGEM 1 μl 
- Buffer 2X 5 μl 
- T4 DNA ligase 1 μl 
- H20 1,5 μl 
O/N at 4°C. 
The day after transformation reaction is performed: 4 μl of the ligation mix is 
added to 100 μl of DH5α competent cells, in a pre-chilled tube. The mix is 
incubated 30‟ in ice, then heated for 1 min at 42°C and then 5‟ in ice. Then 100 μl 
of LB medium is added to the mix, and the batteria is growth at 37°C for 1h. 
Then the mixture is plated in a LB+AMP plate add with X-Gal (80μg/μl) and left 
growth O/N at 37°C. 
The white colony are picked and used to performed a PCR-colony reaction in 
order to verify the presence of the insert: 
- Buffer 10X 1,5μl 
- MgCl2 1,5 μl 
- dNTPs (2mM) 3 μl 
- PRIMER FW+RV 0,6+0,6 μl 
- Taq GOLD 0,1 μl 
- H2O 6,7 μl 
- DNA 1 μl 
Thermocycler program: 
 
Temperature Time Cycle 
96°C 7 min 1 
96°C 30 sec  
35 53°C 45 sec 
72°C 1 min 
72°C 7 min 1 
 
The colony which showed to have the insert is inoculated in 2 ml di LB+AMP, to 
proceed to DNA extraction (mini prep).  
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The correct mini prep is restricted with the specific restriction enzyme as 
indicated: 
- 14μl mini prep 
- 1 μl EcoRI (Fermentas) 
- 1 μl HindIII (Fermentas) 
- 4 μl TANGO Buffer 2X 
O/N at 37°C. 
The restriction is verified on agarose gel 1%, the residual mix is then loaded on a 
crystal violet gel (60 ml of TBE and 30 μl of crystal violet) to extract the digest 
insert. The insert was then extract from the gel using a kit (Quiagen).  
The vector is restricted  and dephosphorylated by added 1μl of CIAP enzyme 
(fermnetas), the mix is incubated for 30‟ at 37°C, then the enzyme is inactivated at 
65°C for 5‟ and then in ice. Finally, the dephosphorilated insert is purified by 
plate (Millipore) and is resuspended in 40μl of MilliQ water. 
The ligation reaction is performed as indicated: 
- 2 μl Buffer 10X 
- 1 μl T4 DNA ligase (Fermentas) 
      - 12 μl PTEN (EcoRI/HindIII) 
      -  1,5 μl pcDNA 3.1 (-)PURO (EcoRI/HindIII) 
      - 3,5 μl H2O  
O/N at 16°C. 
The ligation reaction is then transformed in DH5α, following the protocol 
described above, and finally plated in LB+AMP (37°C O/N). The colony is 
picked up, inoculated in 2 ml LB+AMP for DNA extraction (mini-prep). 
DNA extracted is then sequenced to verify the presence of insert, its right 
orientation and the frame with vector sequence. Finally, the correct insert is 
inoculated in 50ml LB+AMP, for midi prep extraction (Roche). 
 
FLCN cDNA is cloned in two different vectors pcDNA 3.1(+)ZEO and pcDNA 
3.1(-)PURO. Before being inserted in pcDNA 3.1(-)PURO, FLCN is cloned in 
pcDNA3.1mycHis vector, in order to inserted the myc flag at 3‟end. 
The following primers are used for the cloning: 
FLCN-EcoRV-FW TAGATATCCGCCACCATGAATGCCATCGTGGCT 
FLCN-XhOI-RV ATCTCGAGCGTTCCGAGACTCCGAGGC 
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Then FLCN-myc is cloned in pcDNA3.1 (-)PURO, using the following primers: 
FLCN-EcoRV-FW TAGATATCCGCCACCATGAATGCCATCGTGGCT 
FLCN-BamHI-RV TGGATCCTCAATGGTGATGGTGATGATGACCGGT 
The PCR mix is performed as indicated: 
- 2,5 μl dNTPs 
- 2,5 μl Buffer 10X 
- 0,2 μl Taq EasyA 
- 1 μl insert 
- 17,3 μl H2O 
Theromcycler is programmed as following reported: 
Temperature Time Cycle 
95°C 2 min 1 
95°C 40 sec  
30 60°C 30 sec 
72°C 12 min 
72°C 10 min 1 
 
The PCR product is purified by gel extraction (SIGMA) and then restricted with 
the specific restriction enzyme. Then is transformed in pGEM vector (Promega). 
The double digestion is performed in two following step. 
FLCN and pcDNA 3.1 (-) PURO is first digested with EcoRV (NEB): 
-12 μl FLCN/ 10 μl pcDNA 3.1(-)PURO 
- 1 μl EcoRV (NEB) 
- 0,2 μl BSA 100X 
- 2 μl Buffer 10X 
- 4,8/6,8 μl H2O 
O/N at 37°C. 
The restriction is verified on 1% gel agarose and then purified, by purification 
plate (Millipore), before proceeding to the second digestion. 
Then all the purified PCR product is used for the digestion reaction with BamHI 
(Fermentas): 
- 17μl insert/pcDNA 3.1(-) 
- 2 μl Buffer 10X 
- 1 μl  BamHI(Fermentas) 
37°C O/N. 
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The pcDNA 3.1(-)PURO is dephosphorylated with the use of CIAP enzyme, and 
then purified by plate (Millipore). FLCN is loaded a crystal violet gel and then 
extracted with a kit (Sigma). The ligation reaction is performed as indicated: 
-2μl Buffer 10X 
- 1 μl T4DNA ligase  
- 9,9 μl FLCN 
- 1,3 μl pcDNA 3.1(-)PURO 
-5,8 μl H2O 
16°C O/N 
All the successive steps followed the same protocol used for PTEN cloning. 
FLCN is finally cloned in pcDNA3.1(+)ZEO. FLCN in pGEM vector  and 
pcDNA 3.1(+)ZEO is both digested with EcoRV and NotI (Roche). Then the 
ligation is performed following the protocol described before. All the successive 
steps followed the same protocol of the other cloning. 
Transfection 
Cells is seeded the day before in concentration that allow to reach the 70-90% of 
confluence in 24 h. The transfection reaction is performed using the X-treme 
GENE HP DNA Transfction Reagent (roche), following the manufacturer 
protocol. 
Prepare in a tube 200 μl(for a 6 wells dishes) and 600 μl (for a T25 flask) of serum 
free medium and add 2 μg or 6 μg, respectively for a 6 wells and for a flask, of 
transfection reagent. Mix well and incubate for 15‟ at RT. Add directly the mix, 
containingthe plasmid and the transfection reagent, to the cell culture without 
changing the medium. Then , the cells are incubated at 37°C for 48h.  
Cellular lysate 
The cells are first pelleted at 1500g for 5‟, then the medium is removed and the 
pellet is washed twice with PBS buffer. 
The pellet is resuspended in RIPA buffer (Tris-HCl pH7.4 50mM, NaCl 150mM, 
SDS 0,1%, Triton-X 1%, EDTA 1mM) with Phosphatases Inhibitor (10X-
Roche)+ Protease Inhibitor (25X-Roche)+NaOV3 (Tyrosine Phosphatase 
Inhibitor-1mM). 
The suspenction is incubated for 15‟ in ice, then is passed, at least 4 time, through 
an insuline syringe.Then it is frozen and thawed twice and centrifuged 10‟ at 
13.000rpm at 4°C. Finally the supernatant is transferred in a new tube. 
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Proteins lysates are quantified using the Lowry High Standard Curve method 
(Bio-Rad) following the manufacturer instruction.  
 
 
SDS_Page and Western blot 
40 μg of proteins are loaded on 10% poly-acrilammide gel. The protein is 
resuspended in Laemly Buffer (Tris-HCl pH 6.8 125mM, 4% SDS, glicerol 20%, 
bromo-phenol blue 0,000025% and β-mercaptoethanol 10%). The samples is 
denaturated at 99 °C for 5‟. 
Run is performed in Running Buffer 1X (Tris pH 8.3 25 mM, glycine 193 mM, 
SDS 1%) at 120 V for ~2 hours. At the end of the run the proteins are transfered 
on nitrocellulose membrane (Perkin-Elmer). The transfer is performed in pre-
chilled Transfer Buffer solution 1 X (Tris pH 8.3 25mM glycine 193 mM, 
methanol 20%) at 300mA for 1 hour at 4°C. 
Western blotting is performed following the WesternBreeze® Chemiluminescent 
Water Blot Immunodetection Kit (Invitrogen). After transfer the nitrocellulose 
membrane is incubated in Blocking Solution (Blocker/Diluent A: concentrated 
buffered saline solution containing detergent, Blocker/Diluent B: concentrated 
hammersten casein solution, e H2O) for at least 30‟. 
Primary antibodies are diluited in Blocking Solution and incubated for 1 hour at 
RT. 
For the experiments are utilized the following primary antibodies: 
- Mouse anti-PTEN (Cascade Bioscience) 1:1000 
- Rabbit anti-p16 (Santa Cruz)  1:500 
- Rabbit anti-p21 (Santa Cruz) 1:1000 
- Mouse anti-p53 (Santa Cruz) 1:1000 
- Rabbit anti-p70S6K1 (Cell Signaling) 1:1000 
- Rabbit anti-Phospho-p70S6K1 (Cell Signaling) 1:1000 
- Mouse anti-Myc (Invitrogen) 1:1000 
- Rabbit anti-NDUFA9 (Santa Cruz Biotecnology) 1:2000 
- Rabbit anti-SDHA-SDHB (Mitosciences)  1:1000 
- Rabbit-ATPase5B 1:1000 
- Mouse anti-TFAM (Santa Cruz Biotecnology) 1:10000 
- Mouse anti-Catalase (Bethyl laboratories) 1:1000 
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- Rabbit anti-Prx3 (LabFrontiers) 1:100000 
- Rabbit anti-MnSOD (Invitrogen) 1:1000 
- Mouse anti-Tubulin (Sigma) 1:10000  
- Mouse anti-Actin  (Sigma) 1:10000 
Then the nitrocellulose membrane is washed 3 times for 5‟ in Wash Solution 
(concentrated buffered saline solution containing detergent), the membrane is 
incubated with secondary antibodies for 30‟(anti-mouse or anti-rabbit). 
Then the membrane is washed 3 times for 5‟ in wash solution and twice with 
water. Finally Chemioluminescent Substrate (Solution of CDP-star 
chemiluminescent substrate for alcaline phosphatase e Chemiluminescent 
Substrate Enancher) is added and incubated for 5‟ before proceeding to the 
developing.  
RNA extraction  
RNA extraction was performed using the Trizol reagent (Invitrogen) according to 
the manifacturer protocol.  
Cells are first pelleted at 1500 rpm for 5‟, then the pellet are washed twice in PBS 
buffer.The pellet is re-suspended in 300 μL of Trizol Reagent and transfered in a 
new tube.Follows an incubation a RT for 5‟. 
60 μL of chloroform are added to separated the two phases. The tube is shaker 15” 
in hands and then incubated at RT for 2-3‟. Then the tube is centrifugated at 
12.000g for 15‟ at 4°C. The aqueous phase is removed avoid drawing any of the 
interphase or organic layer, and transferred to a new tube and the RNA isolation 
phase begins. 
200 μL of isopropanol is added and the mix is incubated 10‟ at RT. Then is 
centrifugated at 1200g for 10‟ at 4°C. The supernatant is removed to leave only 
the pellet in the tube. The pellet is washed by adding 200μL of ethanol (70%) and 
centrifugated at 7500g at 5‟. Finally the ethanol is removed, the pellet is air dried, 
but not completely to avoid that the pellet can loose solubility. 
Then the pellet is resuspended in 20-40 μL of RNAase-free water and incubated 
for 10‟ at 55°C-60°C to help resuspension. The integrity of the RNA is verified on 
electrophoresis gel at 1%. For the quantification is utilized the Nanodrop (Thermo 
Scientific). 
Reverse transcription (RT-PCR) 
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RT-PCR was performed using the GoScript
TM
  Reverse Transcription System kit 
(Promega) according to the manufacturer protocol.   
1μg of total RNA is transcripted 
A mix is made combiningthe following reagents: 
1. total RNA 1μg/reaction 
2. 1μL Random Primers (0.5μg/reaction) 
3. Nuclease Free water X μL 
To the final volume of 5μL. 
The mix is heated at 70°C in a heat block for 5‟ and then chilly in ice for 5‟. 
Then the transcription mix, containing the Reverse Transcriptase enzyme, is 
prepared as indicated (final volume 15 μL): 
 
GoScript 5X Reaction Buffer  4 μL 
MgCl2 (1.5-5mM) 1.2-6.4 μL  
PCR nucleotideMix (0.5mM each) 1 μL  
GoScript TM RT 1 μL 
ddH2O 6 μL  
 
The reaction is then performed in the thermocycler (Applied Byosistem 2700 PCR 
System): 
 
Temperature Time Cycle 
25°C 5 minuti 1 
42°C 1 ora 1 
70°C 1 minuto 1 
 
Semi-quantitative PCR 
The semi-quantitative PCR was performed on the cDNA to verify the efficacy of 
retrotrascription. A house keeping gene (tubulin) was amplified being sure of its 
expression in all tissue. 
cDNA has been used at different diluitions (1:1, 1:10, 1:100, 1:1000) 
The mix is prepared ad indicated (15 μL): 
1. cDNA 1μL 
2. 2. Buffer 10X 2.5 μL 
3. dNTPs 2.5 μL 
4. Taq GOLD (Invitrogen) 0.2 μL 
5. MgCl2 (25mM)  1.5 μL 
6. Primer FW (10 μmol) 1 μL 
7. Primer Reverse (10 μmol) 1 μL 
8. H2O X μL 
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The reaction is then performed in the thermocycler  
Temperature Time Cycle 
96°C 5 minuti 1 
94°C 30 secondi  
30 61°C 30 secondi 
72°C 30 secondi 
72°C 7 minuti 1 
              Real Time quantitative PCR (qRT-PCR) 
The quantitative real time PCR was performed using the reverse transcriptase mix 
GoTaq-qPCR Master Mix (Promega). 
The reaction mix is performed as indicate (20 μL) 
1. GoTaq Master Mix  10 μL  
2. Primer Forward  1 μL 
3. Primer Reverse 1 μL 
4. cDNA  2μL 
5. H2O  6 μL 
The reaction is performed in the 7500 Fast Real Time PCR System (Applied 
Biosystem), the machine program is: 
Temperature Time Cycle 
95°C 5 minutes 1 
95°C 10 second  
40 59°C 20 second 
60°C 30 second 
 
 
Analysis was performed using both the ΔCt and the ΔΔCt statistical metod 
(Kenneth J.Livak and Thomas D.Schmitthen. Methods 25 402-408 (2001). 
Sequencing Human Mitochondrial DNA with the mitoSEQr
TM
 kit (Applied 
Biosystem) 
The mitoSEQr system (MitoAll) supplied by Applied Biosystem is an innovative 
kit designed for sequencing the whole mitochondrial genome from total DNA. A 
set of 46 primer pairs amplifies, partly overlapping, fragments covering the whole 
mitochondrial genome and permits to obtain the sequence of the entire 16.6Kb 
long mitochondrial chromosome. Another set of 9 primers is designed to sequence 
the D-loop region (about 1.1Kb). 
All these primer pairs anneal at the same temperature allowing to perform all the 
46 amplifications in one single step. Each primer is also tailed with a universal 
M13 sequence tag on the 5‟ end to permit sequencing with M13 primers which 
allow using only one sequencing reaction mix for all amplicons. 
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PCR amplification 
Amplification is carried out in a final volume of 10 μl on a thermocycler (applied 
Biosystem GeneAmp 9700 or 2700 PCR System). Each amplification reaction 
contained. 
 
Master mix ampliTaq Gold 2X 5 μL 
Human genomic DNA(0.5ng/μl) 1 μL 
PCR primer mix (0,6 pmol/μL) 2 μL 
Glycerol 50% 1,6 μL 
ddH2O 0,4 μL 
 
The reaction was performed in a thermocycler following the protocol below:  
Temperatur Time Cycle 
96°C 5 min 1 
94°C 30 sec  
45 60°C 45 sec 
72°C 45 sec 
72°C 10 min 1 
 
The positive outcome of the PCR reaction is verified by loading a part of the PCR 
on a agarose gel. 
Agarose Gel Electrophoresis 
The positive outcome of the reaction is verified by loading a part of the PCR on 
an agarose gel. 
2% and 1% agarose gel is made up with standard 1X TBE buffer (0.05M Tris, 
0.05 M boric acid, 0.01 M EDTA) incorporating Ethidium Bromide at a 
concentration of 0.5 μg/ml (corresponding to 5 μl of EtBr (100mg/ml) in a 100 ml 
gel). 2μl of each PCR reaction was added to one volume of water plus loading dye 
(6X), 2μl (100ng/μl) of 1 Kb or 100 bp DNA Ladder (Invitrogen) were loaded 
into one well on each row of wells on the gel. The gel is run at 100V for 20‟, then 
the gel is visualized with a UV trans-illuminator at  λ 254 nm. 
PCR cleanup 
PCR products diluited in sterile water to a final volume of 120μl is transferred to a 
filetr plate which is placed in a vacuum filtration manifold. A vacuum pressure of 
approximately 250-380mmHg is applied for 5 minutes or until the plate was dry. 
Plates is removed from filtration manifold and 50μl of MilliQ water is added to 
each well. Filter plate is then placed on a shaker and gently shaken to resuspend 
DNA. Finallly, PCR product is purified and can be transferred in a new plate. 
Sequencing reaction 
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For the sequencing reaction are used the reagents supplied by Applied Biosystem. 
The reaction is prepared as indicated: 
Big Dye Terminator v.3.1 RR mix 0,5 μL 
Primer FW o RV (M13) (3,2 pMol) 1 μL 
Buffer 5X 2 μL 
PCR purificata 2 μL 
ddH2O 4,5 μL 
  
  
The reaction was performed in a thermocycler (Applied Byosistem 2700 PCR 
System) following the protocol below  
Temperature Time Cycle 
96°C 1 min 1 
96°C 10 sec  
30 50°C 5 sec 
60°C 4 min 
 
For the sequences analysis is utilized the software SeqScape v.25.  
Copy number assay UPL (Roche) 
The copy number assay is performed to evaluate the occurrence of LOH in CS 
and BHD patients and XTC.UC1 cell line. The experiment is designed using the 
Universal Probe Library (Roche) technique. A set of primers are designed along 
both FLCN and PTEN  gene and the corresponding probes are used to perform the 
assay:  
FLCN  
Exon 4 
FW GGGATGGGAATGAGGACAG 
RV CCGACTGTTCATCTGAATGG 
Probe 35 
 
Exon9 
FW CTGTCCTTGTCATCTGTCTTGC 
RV TCTCCTCCTCTTCAGCCTCA 
Probe 33 
 
Exon 14 
FW ACAGGGATGGCTGTCCAC 
RV GCTTCCTTCCAGCAGTTGAGA 
Probe 19 
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PTEN 
Exon 1 
FW ACTTGACCTGTATCCATTTCTGC 
RV TCCGTCTACTCCCACGTTCTA 
Probe68 
 
Exon 9 
FW GCTGAGGCAGGCAGATTG 
RV GTAGAAATGGGGTTCATGATGTT 
Probe 64 
The DNA is first quantified, an optimal concentration is established in 20 ng/μL 
or 40 ng/μL. Primer concentration is optimezed at 0.5 μM .The reaction mix 
comprises (10μl): 
10 μl Master mix 
1+1 μl Primer FW+RV 
0.2 μl Probes 
5.8 μl H2O 
Then 2 μl of DNA is added. 
The reaction is performed in the LightCycler 480 Real Time PCR System (Roche 
Diagnostic). The machine program is: 
95°Cx5‟ 
95°Cx15‟ 
60°Cx1‟          x40 
 
PTEN, H-Ras, K-Ras, TP53 sequencing 
For PTEN, FLCN, H-Ras, K-Ras and TP53 sequencing specific primers are 
designed through the software Primer 3 ( Appendice A). 
The reaction is performed using FastStart Taq DNA polymerase (Roche) for 
PTEN, K-Ras and TP53, with Master Mix Kapa 2X (Resnova) for H-Ras and with 
Master Mix Taq GOLD (Applied Biosystem) for FLCN. 
The PCR is purified with Multiscreen Filter Plates DNA clean-up (Millipore). For 
the sequencing is used the Sanger technique and the Big-Dye v3.1 (Applied 
Biosystem) as previously described. The mutations are confirmed through 
sequencing the two DNA strand, and on a second PCR.   
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Prediction of mutation effect: PolyPhen 
PolyPhen (Plymorphism Phenotyping) is a software used to predict the possible 
effect of an amino acid substitution in a protein. The program is based on the 
comparison of homologous proteins. The profile score (PSIC) that is generated for 
each allelic variant, represents the ratio between the probability of one amino acid 
in a specific site to the probability of the same amino acid if present in another 
site. A PSIC corresponding to 2 indicates a damaging effect, a score between 1,5 
and 2 suggests  that the variant is possible damaging, instead if the score is low 
than 1,5 the variant is benign. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
 
 
 
 
 
 
3. AIM OF THE STUDY 
 
γ-rays, commonly used in radiotherapy for the treatment of patients affected by 
several type of tumors, could activate mitochondrial biogenesis and cellular 
senescence. However to date, whether the two processes are related to each other 
has not been yet demonstrated.   
The main purpose of this project is to assess whether mitochondrial biogenesis 
and cellular senescence can be activated in the same cells following exposure to a 
genotoxic stress, and if the induction of mitochondrial biogenesis may prelude  
the activation of cellular senescence. 
The study of the oncocytic model XTC.UC1 will also enable us to determine 
whether the presence of mitochondrial dysfunction, induced by mtDNA 
mutations, may contribute to senescence activation.  
Assuming that mitochondrial biogenesis and senescence are regulated by the same 
molecular pathway, induced by genotoixic stress, the second aim of this thesis  is 
to determine the involvement of mTOR, and in particular of mTORC1, in the 
regulation of cell response to γ-rays treatment. Experimental data have indeed 
demonstrated the role of mTOR in regulating both mitochondrial biogenesis and 
certain types of cellular senescence.  
Another objective of the study is to determine which mechanism induce the 
development of oncocytoma in patients affected by two hereditary familial 
syndrome,  CS syndrome and BHD syndrome.  
The study of CS and BHD patients suggests that the double heterozigous of the 
two tumor suppressor genes causative of the syndromes, respectively PTEN and 
FLCN, leads to mitochondrial biogenesis activation.  
In fact, mutations and/or deletion in PTEN and FLCN have been found in 
oncoytomas developed by patients affected by CS and BHD.  
Based on extant knowledge on the role of PTEN and FLCN, it has been 
hypothesized that the genes regulate PGC-1α through the involvement of 
mTORC1.  In order to test this hypothesis, XTC.UC1 cell line which reproduces 
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in vitro what observed in vivo in CS and BHD oncocitomas, has been used to 
determine the effects of  PTEN and FLCN restore expression on PGC-1α 
expression.  
 
 
4. RESULTS 
 
 
4.1 STUDY OF THE LINK BETWEEN SENESCENCE AND MITOCHONDRIAL 
BIOGENESIS INDUCED BY γ-RAYS TREATMENT 
γ-rays are commonly used in radiotherapy for the treatment of patients affected by 
various types of tumors. It has been demonstrated that genotoxic stress induced in 
cells by γ-ray could determine the activation of mitochondrial biogenesis, which 
can lead to the transformation of cells towards an oncocytic phenotype. 
The increase in mtDNA copy number, an index of activation of mitocondrial 
biogenesis, was observed in some tissues, in particular in spleen and brain of 
irradiated mouse models [167, 168]. Furthermore, some patients affected by 
colon-rectal tumors, which underwent preoperative radiotherapy, have developed 
relapses with oncocytic features [169, 170]. 
γ-rays lead to DNA damage mainly in the form of double-strand breaks and can 
result in the activation of cellular senescence [52, 53]. The senescence is defined 
as an irreversible arrest of cellular proliferation [1], and is considered, as 
apoptosis, a mechanism that cells can use in order to limit tumor growth [70]. 
Genotoxic stress can induce the activation of mitochondrial biogenesis and thus 
the differentiation of cells towards an oncocytic phenotype and even the activation 
of cellular senescence. The main objective of this thesis was to clarify if 
mitochondrial biogenesis and senescence could be induced in the same cell line 
after γ-ray treatment.  
It has been hypothesized that genotoxic stress induces initially mitochondrial 
biogenesis which may support the activation and/or the maintenance of the 
senescence phenotype.  
Experiments evaluating the activation of mitochondrial biogenesis in response to 
γ-ray treatments of the cell lines RPE1 and HCT116 had already been conducted 
in the laboratory of Medical Genetics. 
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The HCT116 cell line derived from a colon-rectal carcinoma and it has been 
chosen for the study because the relapses with oncocytic features after 
radiotherapy had been observed in patients with colonrectal tumors [169, 170]. 
The RPE1 cell line has been selected because it is a non tumor cell line which 
allows to understand the effect of γ-rays on a normal tissue. 
To establish the effects of genotoxic stress on mitochondrial biogenesis several 
indexes of biogenesis, such as changes of expression of some mitochondrial 
proteins and mtDNA copy numbers, have been evaluated. Figure 12 and 13 report 
the experiments conducted respectively on HCT116 and RPE1 cell lines. 
In the HCT116 cell line it has been show that genotoxic stress causes an increase 
in mtDNA copy number observed after 3 days of irradiation (IR3) which remains 
constant after 120 hours of recovery (RL). Also an increased expression of some 
proteins of the respiratory chain complexes, in particular NDUFA9 subunity for 
complex I, SDHA and SDHB for complex II and the mitochondrial transcriptional 
factor TFAM, has been observed. 
Even in the RPE1 cell line a genotoxic stress induced the increase in mtDNA copy 
number (it was observed after 4 days of irradiation (IR4) and remained constant 
after 120 hours of recovery (RL)) as well as the increased expression of some 
mitochondrial proteins (NDUFA9, SDHA, SDHB and TFAM).   
The increase of mtDNA copy number and the increased expression of 
mitochondrial proteins demonstrated that genotoxic stress induced in RPE1 and 
HCT116 cell lines the activation of mitochondrial biogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
Tubulin  
TFAM
  
SDHB
  
SDHA
  
NDUFA9
  
T0  IR3  RL 
 
A B 
 52 
Fig.12: A Mitochondrial proteins expression in HCT116 cell line after γ-rays treatment B: mtDNA 
copy number after γ-rays exposure  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.13: A Mitochondrial proteins expression in RPE1 cell line after γ-rays treatment B: mtDNA 
copy number after γ-rays exposure  
 
4.1.1 Sequencing of TP53, PTEN, H-Ras and K-Ras genes 
In order to understand how the genotype of some oncogenes and tumor suppressor 
genes may affect the ability of cells to activate senescence after exposure to γ-
rays, RPE1 and HCT116 cell lines as well as the only existing model of oncocytic 
tumor, the XTC.UC1 cell line, were analyzed in order to identify mutations in 
some genes that regulate senescence. 
The response of the XTC.UC1 cell line was studied in order to verify if mutations 
in mtDNA affecting the functionality of respiratory complexes could be involved 
in the activation of cellular senescence.  
Regardless of the stimulus, senescence is regulated in most cases by the tumor 
suppressor gene TP53 [2]. The TP53 gene was therefore sequenced in cell lines in 
order to verify the presence of mutations that might affect the ability of these cells  
to induce senescence. 
Senescence can also be induced by loss of function of tumor suppressor genes 
such as PTEN [46] or by mutations that activate oncogenes, as mutations in H-Ras 
T0  IR4  RL 
NDUFA9
  
SDHA 
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TFAM   
Tubulin 
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[3]. PTEN, H-Ras and K-Ras coding regions were sequenced with the aim of 
verifying the presence of mutations in these cell lines. 
The results of the screening are reported in table 1. 
 
 
 
 
 
  TP53 PTEN K-Ras H-Ras 
XTC.UC1 p. P151T+LOH Del T(67619)+LOH wild type wild type 
RPE1 wild type wild type wild type wild type 
HCT116 wild type wild type p.G13D wild type 
   
Table 1: Results of the sequencing of HCT116, RPE1 e XTC.UC1 cell lines for TP53, PTEN, K-
Ras e H-Ras genes. 
 
Recently an involvement of mitochondria in the process of cellular senescence 
[25] has been shown in cells characterized by the presence of a mutations in H-
Ras (H-Ras
V
12) gene that activate the function of the proto-oncogene. 
The authors have shown that the pharmacological treatment with molecules such 
as rotenone and oligomycin, which act as inhibitors, respectively of complex I and 
ATP synthase, favor the onset of the senescence phenotype [25].   
The mitochondrial genome (mtDNA) of the above mentioned cell lines was 
sequenced with the aim to verify the presence of mtDNA mutations. 
The XTC.UC1 cell line is characterized by the presence of a mutation in TP53. 
The sequencing of this gene has revealed the presence of a missense substitution 
in exon 5 (C13039A) which determines the substitution of a proline in position 
151 with a threonine (Fig.14). The UPL copy number assay showed the loss of the 
wild type allele of TP53.  
Through the use of Polyphen software the potential role of the mutation on protein 
functionality was assessed. The PSIC score assigned to the mutation was 2.731 
and the substitution was defined as “probably damaging” 
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Fig. 14: Electropherogram of TP53 mutation in XTC.UC1 cell line. The left image reported the 
wild type control, in the right image is reported the electropherogram of XTC.UC1 cell line. The 
mutation is indicated by the red arrow. 
 
The amino acid 151 is part of the central domain of p53, also known as DNA 
binding domain (DBD) [58]. Since p53 acts as transcriptional factor, the presence 
of a mutation in this amino acid suggests that the protein loses its ability to 
recognize the DNA sequence and then to activate the transcription of target genes. 
It should be also noted that this mutation lies in exon 5 of TP53 that is a 
mutational hot spot of the gene [171]. Moreover the mutated amino acid precedes 
and follows two amino acids, respectively Thr150 and Ser149, which are two of 
the three phosphorylable amino acids of DBD, whose phosphorylation has been 
shown to increase the protein‟s ability to interact with and recognize DNA 
sequence [58]. It can be hypothesized that the substitution of this amino acid 
could interfere with the ability of kinases to recognize Thr150 and Ser149, with 
the consequent inability of p53 to recognize target genes. 
Sequencing of PTEN in this cell line has shown that it is characterized by the 
presence of a frameshift mutation (deletion of one T) in exon 4 (Fig.15). UPL 
copy number assay demonstrated besides the loss of the wild type PTEN allele. 
These data were confirmed by western blotting assay, which demonstrated that 
XTC.UC1 cell line is null for PTEN (Fig. 15). No mutations were found in H-Ras 
and K-Ras. 
 
 
 
 
 
 
 
 
 
Fig. 15: A: Western blotting showing PTEN expression in a set of cell lines. XTC.UC1 do not 
express PTEN B: Electropherogram showing single base deletion in PTEN exon 4 of XTC.UC1 
RPE1  HEK293  XTC.UC1 
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Moreover XTC.UC1 cells carry the mitochondrial mutation m.3571insC [142]. 
This frameshift mutation inserts a stop codon at amino acid 101 in the ND1 
subunit of complex I, thus generating a truncated protein that is hence degraded. 
Furthermore the XTC.UC1 cell line carries another mtDNA mutation, namely 
m.15557G>A, which causes a non conservative missense substitution (E271K) in 
cytochrome b, the only mtDNA encoded subunit of complex III. Both mutations 
are present in XTC.UC1 cells in a condition of heteroplasmy at 50%. The result is 
the alteration of the functionality of respiratory complexes and of the ability of 
cells to synthesize ATP.  
The HCT116 cell line derived from a colon-rectal tumor; there are not mutations 
in TP53 and PTEN genes, while the presence of mutation in exon 1 of K-Ras gene 
(G5578A), which determines the substitution of a glycine in position 13 in 
aspartate, has been confirmed (Fig.16). This mutation has already been reported in 
literature as a mutation that activates the proto-oncogenic function of this protein 
[172]. 
 
 
 
 
 
 
 
 
 
Fig. 16: Electropherogram showing the mutation in K-Ras exon 1 of HCT116. The mutation is 
reported in panel A and is indicated by the red arrow. B Wild type sequence 
 
With regard to the mtDNA, the insertion of one C in a homopolymeric stretch of 
5C‟s (m.5898incC) has been highlighted (Fig.17). This mutation has no functional 
implications because is localized in a non-coding region.  
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Fig. 17: Electropherogram showing the mtDNA mutation in HCT116 cell line. The insertion of 
one C is indicated by the red arrow. 
 
Finally, in the RPE1 cell line no mutations were found in PTEN, K-Ras, H-Ras 
and in mtDNA  
 
4.1.2 Cellular response to a genotoxic stress: cellular senescence 
In order to determine the response of RPE1, HCT116 and XTC.UC1 to genotoxic 
stress in terms of activation of cellular senescence, the above mentioned cell lines 
have been subjected to treatment with γ-rays following the protocol previously 
optimized for each cell line (Table 2). The optimal dose of radiation to be 
administrated to cells was chosen such as to be able to induce an appreciable 
effect on the phenotype while maintaining cell viability.  
 
  RPE1 
T0 Untreated control 
IR4 4 doses of 4 Gy 
RL 4 doses of 4 Gy and 120 hours of recovery  
 
  XTC.UC1 
T0 Untreated control 
IR4 4 doses of 4 Gy 
RL 4 doses of 4 Gy and 120 hours of recovery 
 
  HCT116 
T0 Untreated control 
IR3 3 doses of 4 Gy 
RL 3 doses of 4 Gy and 120 hours of recovery  
 
Table 2: Protocol of irradiation relative to each cell line 
 
To date no univocal assay that can be used to determine the induction of 
senescence has been defined, but the marker that is commonly used to assess the 
activation of the process is a cytochemical assay aimed at assessing the activity of 
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the lisosomal enzyme β-galactosidase (SA-βGal). It has been demonstrated that 
senescent cells are characterized by an increased activity of this enzyme [27] 
whose contribution to senescence has not yet been elucidated. 
Even the microscopic observation of morphological changes induced in cells after 
genotoxic stress was used as a parameter to determine the activation of 
senescence. In fact it was demonstrated that a senescent cell is characterized by 
the acquisition of a series of morphological changes such as: increase in size, 
flattened and shaped morphology and in some types of senescence cytoplasmic 
vacuoles may occur [10] (Fig.18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.18: A: Cytoplasmic vacuoles typicall of H-Ras induced senescence (Moiseva et al., 2009) B: 
Fibroblats stained with SA-β-gal, senescent cells  are blue(Funayama and Fuyuki 2007) C: 
Senescent cells show a large and flat morphoplogy and chromatin condensation (Funayama and 
Fuyuki 2007). 
 
To confirm that genotoxic stress induces in cells a proliferative arrest, the 
distribution of cells in the different cell cycle phases (G0/G1-S-G2/M) was 
evaluated by flow cytometry. Senescent cells stop generally with a typical DNA 
content of G1 phase [16], although this may vary depending on the cell lines [2]. 
In general, the activation of senescence should result in a decrease in the 
percentage of S phases cells which results in a redistribution in the other two 
phases of the cell cycle (G0/G1-G2/M), which may vary depending on cell type.  
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Regardless of the stimulus that induces senescence, it was demonstrated that the 
pathways of p53 and p16
INK4A
-pRB are the two effector pathways of senescence 
that determine not only the blocking of cell proliferation but also regulate the 
appearance of most of the morphological changes typical of a senescent cell. It 
has been shown that these two pathways may interact or act independently in 
regulating senescence [2]. In order to determine which of these two pathways was 
involved in regulating the activation of senescence induced by genotoxic stress, 
the expression of p16, p53 and p21 was evaluated. 
RPE1 
The images of the SA-β-Gal assay of the RPE1 cell line are reported in figure 19.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.19: SA-β-Gal assay of RPE1 cell line: after γ-rays treatment cells were fixed and incubated 
with SA-β-Gal staining solution O/N. Cells were washed and then microphotographed (10X). 
T0: untreated control RL: cells treated for 4 days at 4 Gy and after 120 hours of recovery.  
 
The positivity of the irradiated RPE1 to the β-galactosidase assay showed that the 
genotoxic stress induces the activation of the cellular senescence. Furthermore the 
irradiated cells increase in size and become more flattened with respect to the 
untreated control.  
Analysis of the cell distribution during different cell cycle phases showed that 
genotoxic stress caused the block of proliferation (Fig.20).  
RPE1-RL 
RPE1-T0 
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In fact, following γ-rays treatment a decrease in the percentage of cells 
undergoing S phase was observed (from 18% in the T0 to the 9% in the irradiated 
cells) as well as a re-distribution of  cells between the G0/G1 phase and G2/M 
phases. Taken together, these results show that genotoxic stress induces in these 
cells the activation of the cellular senescence. 
 
 
 
 
 
 
 
 
 
 
  RPE1-TO RPE1-RL 
GO/G1 60% 53% 
S 18% 9% 
G2/M 20% 30% 
 
Fig. 20: Analysis of cells distribution in the cell cycle phases after staining with PI by flow 
cytometry. T0: untreated control  RL: cells irradiated 4 days at 4Gy and after 120 hours of 
recovery. 
 
To determine which molecular pathway regulates this process, in particular 
whether p53-p21 and/or p16-pRb pathways could be involved, changes in 
expression of these proteins were determined by western blotting assay (Fig.21).  
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Fig. 21: Effect of γ-rays treatment on p16, p53 and p21 expression. RPE1 cells were irradiated as 
indicated, lysates of these cells were collected and immunoblotted with the indicated antibodies. 
Tubulin is used as a loading control T0:untreated control IR4: cells irradiated 4 days at 4 Gy. RL: 
cells irradiated 4 days at 4 Gy and after 120 hours of recovery. 
 
The treatment with γ-rays of the RPE1 cell line determined an increase of p53 and 
p21 expression, while with regard to p16 a decrease was observed.  
The increase in p53 expression, which was observed after 4 days of irradiation 
(IR4) and remained unchanged even after 120 hours of recovery (RL), and the 
consequent increase of p21 expression (which maintains the same performance of 
its regulator p53) leads us to conclude that senescence induced by genotoxic stress 
in RPE1 cell line is dependent on the activation of the p53-p21 pathway, while the 
Rb-p16 pathway is not involved.   
 
HCT116 
Figure 22 shows the images of the SA-β-Gal assay performed on the HCT116 cell 
line following γ-rays treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22: SA-β-Gal assay for HCT116 cell line: after γ-rays exposure cells were fixed and 
incubated with SA-β-Gal staining solution O/N. Cells were washed and then microphotographed 
(10X). T0: untreated control RL: cells treated for 3 days at 4 Gy and after 120 hours of recovery.  
HCT116-RL 
HCT116-T0 
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Also in the HCT116 cell line, the genotoxic stress induced the activation of 
cellular senescence, as demonstrated by the positivity of the irradiated cell line 
(HCT116 RL) compared to the control (HCT116 T0) in the β-galactosidase assay.    
After the γ rays treatment the increase in cell size and the change in cell 
morfology was observed. Interestingly, the distinctive characteristic of this line 
was the appearance of numerous cytoplasmic vacuoles, which lead to a reduction 
of the cytoplasmic volume.  
As previously discussed, it is possible to observe the appearance of vacuoles in H-
Ras induced senescence (H-Ras 
V
12) [20]. The sequencing of K-Ras conducted at 
the beginning of the study demonstrated the presence of a mutation in this gene, in 
HCT116 cell line, which would explain the appearance of these vacuoles after 
activation of the senescence program.  
Subsequently, the distribution of cells in different phases of the cell cycle was 
analyzed after staining with PI and analysis by flow cytometry (Fig. 23). 
 
 
 
 
 
 
 
 
  HCT116-TO HCT116-RL 
GO/G1 55.6%   57.1%   
S 19.1%   13.2% 
G2/M 22.7% 25.3%   
 
Fig. 23: Analysis of cells distribution in the cell cycle phases after staining with PI by flow 
cytometry. T0: untreated control  RL: cells irradiated 3 days at 4Gy and after 120 hours of 
recovery. 
  
The HCT116 cell line is characterized by the presence of a frameshift mutation in 
the CDKN2A gene coding for p16. Consequently the senescence observed in this 
cell line probably depends on the p53-p21 pathway. To confirm that p53 and p21 
HCT116-T0 HCT116-RL 
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are effectory of senescence induced in these cells by genotoxic stress, the 
expression of p53 and p21 was assessed by western blotting (Fig. 24). The 
treatment with γ-rays determined the increase of p53 and p21, already visible after 
3 days of irradiation (IR3) which remained constant even after 120 hours after the 
end of treatment (RL). Therefore, in the HCT116 cell line  the genotoxic stress 
caused the activation of cellular senescence whose induction involved the p53-p21 
pathway.  
 
 
 
                                                    
 
 
 
 
Fig. 24: Effect of γ-rays treatment on p16, p53 and p21 expression. HCT116 were irradiated, at the 
indicated in figure lysates of these cells were collected and immunoblotted with the indicated 
antibodies. Tubulin is used as a loading control. T0:untreated control IR3: cells irradiated 3 days 
at 4 Gy. RL: cells irradiated 3 days at 4 Gy and after 120 hours of recovery. 
 
XTC.UC1 
The SA-β-Gal assay of the XTC.UC1 cell line is shown in figure 25. 
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Fig.25: SA-β-Gal assay for XTC.UC1 cell line: after γ-rays treatment cells were fixed and 
incubated with SA-β-Gal staining solution O/N. Cells were washed and microphotographed (20X). 
T0: untreated control RL: cells treated for 4 days at 4 Gy and after 120 hours of recovery.  
 
The strong positivity of XTC.UC1 subjected to treatment with γ-rays (XTC.UC1-
RL) compared to the untreated control (XTC.UC1-T0) demonstrated that 
genotoxic stress in this cell line induced the activation of senescence. Similarly to 
RPE1 and HCT116, a marked alteration of cell morphology was observed in 
XTC.UC1 as well. Following the γ-rays treatment the cells increased in size, 
became more flattened and  in some cases fusiform. Moreover, the appearance of 
numerous cytoplasmic vacuoles was observed, which in some cases occupy 
almost the total cytoplasmic volume.  
To confirm the proliferative arrest, the distribution of cells in the different cell 
cycle phases will be evaluated by flow cytometry.  
In order to determine the molecular pathway activated in the cells as a result of 
the γ-rays treatment, which could be responsible to determine the proliferative 
block, expression of p53, p21 and p16 were evaluated in irradiated XTC.UC1. 
Since this cell line is characterized, as shown from the TP53 screening, by the 
presence of a mutation predicted as probably damaging, the hypothesis is that 
senescence observed in this cell line depends exclusively on the pRb-p16 
pathway. Although the genotoxic stress did not cause an increase of p53 
expression, an increase of p21 was observed. Instead, there were no changes in 
p16 expression following treatment with γ-rays (Fig.26). This result indicated that 
the increase of p21 expression observed in XTC.UC1 cell line is regulated by a 
mechanism independent from p53 action, and that only p21 is the activated 
senescence effector in this cell line upon genotoxic stress.  
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Fig. 26: Effect of γ-rays treatment on p16, p53 and p21 expression. Cells are irradiated, after the 
end of the treatment and after 120h of recovery, lysates of these cells were collected and 
immunoblotted with the indicated antibodies. Tubulin is used as aloading control. T0:untreated 
control IR4: cells irradiated 4 days at 4 Gy. RL: cells irradiated 4 days at 4 Gy and after 120 hours 
of recovery. 
 
After γ-rays treatment numerous  vacuoles appear in the cytoplasm of XTC.UC1. 
The presence of such vacuoles has been described in certain types of senescence, 
such as in melamocytes in which senescence is induced as a result of the presence 
of mutations in tumor suppressor gene H-Ras (H-Ras 
V
12) [20].  
These cells are characterized by the early appearance of cytoplasmic vacuoles 
which are, as demonstrated by electron microscopy, the result of the endoplasmic 
reticulum membrane expansion . It has been shown that the presence of the H-Ras 
mutation determines the activation of the UPR (unfolded protein response) that is 
directly responsible for activation of senescence processes [20].  
Recently, the appearance of the senescence-related cytoplasmic vacuoles has been 
described even in fibroblasts overexpressing the mutated form of H-Ras. 
The authors describe these vacuoles as deposits of H2O2, which involvement has 
not yet been clarified, and introduce the hypothesis that mitochondria might be 
implicated in supporting the formation of a senescent phenotype [25]. 
In fact, just before the full activation of senescence in a cell, it is possible to 
observe changes in mitochondrial morphology, increase of ROS production, loss 
of mitochondrial potential and increase in expression of certain regulators of the 
mitochondrial biogenesis (NRF2, PGC-1α, PGC-1β e TFAM). 
Moreover, the inhibition of the respiratory chain components by RNA interference 
or pharmacologically have been shown to activate the process of senescence, 
confirming the involvement of mitochondria in the induction of senescence [25].  
As previously discussed, the XTC.UC1 cell line is characterized by the presence 
of two mtDNA mutations negatively affecting the ATP synthesis [142].  
Therefore, it has been hypothesized that the presence of mitochondrial 
dysfunction may be involved in supporting senescence induced in XTC.UC1 
following γ-rays treatment, that is mediated by activation of DNA-damage 
response (DDR).  
The mutations that characterize the XTC.UC1, although present in heteroplasmy, 
cause a reduction of complex I and III activities and it is well known that 
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alterations in the functionality of respiratory complexes can contribute to the 
formation of reactive oxigen species (ROS) [142, 173-175]. It has been suggested, 
therefore, that in XTC.UC1 cell line the continuous production of ROS may 
contribute to the occurrence and maintenance of the senescence phenotype 
amplifying the DDR induced by genotoxic stress. In this context, vacuoles which 
are generated in XTC.UC1 after γ-rays treatment may have a different origin than 
those observed in the HCT116 cell line. In the oncocytic model the vacuoles could 
arise as a result of the increased ROS production. On the other hand, in  the 
HCT116 cell line vacuoles could be formed due to the expansion of endoplasmic 
reticulum and after activation of UPR resulting from the presence of K-Ras 
mutations.  
In order to verify whether the senescence-related vacuoles may have a different 
origin, and to prove whether ROS and subsequent mitochondrial mutations may 
be involved in regulating the activation of senescence, the accumulation of H2O2 
was evaluated in vacuoles of HCT116 and XTC.UC1 cell lines, through the use of 
the probe dichlorodihydrofluorescein diacetate (DCFDA) (Fig. 27).    
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Fig.27: Immunofluorescent image (60X) to visualize the vacuoles in the cytoplasm of HCT116 
and XTC.UC1 cell line stained with DCFDA. XTC.UC1-IR4: cells irradiated 4 days at 4Gy  
XTC.UC1-RL: cells irradiated 4 days at 4Gy and after 120h of recovery. HCT116-RL: cells 
irradiated 3 days at 4Gy and after 120h of recovery. 
 
XTC.UC1 RL 
XTC.UC1 IR4 
HCT116 RL 
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In XTC.UC1 cytoplasmic vacuoles were clearly visible 4 days upon irradiation 
(XTC.UC1-IR4) and their number increased after 120 hours of recovery 
(XTC.UC1-RL). The accumulation of DCFDA in these vacuoles, indicated that 
genotoxic stress in XTC.UC1 cell line causes an increase in ROS production. 
Next, in order to establish that genotoxic stress may lead to increased ROS 
production and sustain the appearance of a senescence phenotype, changes in 
expression of cytosolic and mitochondrial antioxidant enzymes were evaluated. In 
particular, the expression of Manganese Superoxide Dismutase (MnSOD), 
Peroxiredoxin 3 (PRX3) and Catalase (CAT) were evaluated, all enzymes which 
catalyze the ROS detoxification (Fig.28).  
 
 
 
 
 
 
 
 
 
Fig. 28: Expression of antioxidant enzymes (PRX3-Catalase and MnSOD) in XTC.UC1 cell lines 
after γ-rays treatment. Cells were irradiated, then lysates were collected and immunoblotted with 
the indicated antibodies. Tubulin is used as a loading control. T0: untreated control IR4: cells 
irradiated 4days at 4Gy RL: cells irradiated 4 days at 4Gy and after 120h of recovery. 
 
The increased expression of MnSOD, as well as the slight increase of PRX3 
expression, indicating that ROS increase induced by genotoxic stress was 
followed by the overexpression of enzymes that are responsible of the radical 
detoxification. 
In HCT116 vacuoles became visible 120 hours upon recovery (HCT116-RL) but 
did not accumulate the DCFDA probe (Fig.27), which suggested that in this cell 
line the activation of the senescent phenotype did not involve ROS production, 
but was probably determined by the activation of a different molecular 
mechanism. The presence of vacuoles in this cell line after exposure to γ-rays 
treatment, combined to K-Ras mutation, indicated that could be UPR activation to 
lead the induction of senescence phenotype. Further study will be conducted to 
demonstrate that these vacuoles are generated as expansion of endoplasmic 
reticulum.  
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These results lead us to conclude that in XTC.UC1 cell line, genotoxic stress can 
determine the activation of cellular senescence, moreover the increase ROS 
production and antioxidant enzyme expression, indicate that mitochondrial 
dysfunction contribute to the maintenance of senescent phenotype.  
 
4.2 mTOR: A SINGLE PATHWAY MAY REGULATE SENESCENCE AND 
MITOCHONDRIAL BIOGENESIS? 
In the first part of this study it was shown that the genotoxic stress induced by γ-
rays was able to induce the activation of mitochondrial biogenesis and senescence. 
In order to determine which mechanism is activated following γ-rays treatment, 
and if the same pathway can regulate the induction of the two processes, the 
attention was next focused on mTOR pathway and in particular on mTORC1 
complex. 
mTOR is a serine-threonine kinase that regulates several cellular processes 
including protein synthesis, cell growth and proliferation in response to different 
stimuli such as growth factors, nutrients and diverse stresses and changes in 
energy supply [74]. 
Among other, experimental data has also demonstrated the involvement of mTOR 
in regulating certain types of cellular senescence [46, 47, 95, 96]. It has been 
shown that mTORC1 is involved in the induction of PICS (Pten loss Induced 
Senescence) [46, 47]. According to the authors, mTORC1 activated by the lack of 
PTEN acts by enhancing the translation of p53 and thereby supporting the 
activation of senescence. In this model, inhibition of mTORC1 following 
treatment with rapamycin would be sufficient to block the induction of the 
senescence processes [46, 47]. The involvement of mTORC1 in cellular 
senescence has also been demonstrated in human fibroblasts after inactivation of 
the PI3K/AKT pathway [95]. The loss of PI3K/AKT determines the induction of 
cellular senescence that would be controlled by mTORC1 through the 
enhancement of p53 translation [95].    
Furthermore, mTOR, and in particular mTORC1, is responsible for the regulation 
of the mitochondrial metabolism [132]. It has been shown that mTORC1 binds to 
the transcriptional factor YY1 and with PGC-1α, forming a ternary complex 
which controls the transcription of several mitochondrial genes [132]. In 
agreement whit this notion, it was demonstrated that the lack of the principal 
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interacting protein of mTORC1, RAPTOR, is associated with defects of the 
mitochondrial biogenesis in skeletal muscle, leading  to a decrease in oxidative 
capacity of the cells [176].  
Considering the dual role of mTORC1 in the regulation of senescence and  
mitochondrial biogenesis, it may be hypothesized that this complex is responsible 
for the activation of both mitochondrial biogenesis and senescence induced upon 
genotoxic stress.   
To verify this hypothesis RPE1, HCT116 and XTC.UC1 were treated with 
rapamycin, a specific inhibitor of mTORC1 before the γ-rays treatment, in order 
to determine alterations in senescence and mitochondrial biogenesis, resulting 
from inhibition of mTORC1. 
To evaluate the effect of mTORC1 inhibition on the mitochondrial biogenesis 
variations of expression of the proteins that make part of the respiratory 
complexes was evaluated, such as ATPase5B, NDUFA9, SDHA, SDHB and 
TFAM.  
To establish the effect on cellular senescence SA-β-Gal assay was used, and p21 
expression, that is the senescence effector for all the cell lines, was evaluated with 
western blotting assay.  
 
4.2.1  RPE1 and  mTORC1 
In Figure 29 the images of western blotting assay are reported through which the 
expression of the total and phosphorylated forms of the S6K1 kinase were 
evaluated. S6K1 kinase is one of the downstream target of mTORC1, which is 
activated after phosphorilation [90].  
 
 
 
 
 
 
 
Fig. 29: Expression of total and phosphorilated form of S6K1 kinase. Cells were treated with 
rapamycin (10nM) before the irradiation.Tubulin is used as a loading control. T0: untreated 
control RL:cells treated 4 days at 4Gy and after 120h of recovery  RL+R: cells treated with 
rapamycin (10mM), irradiated for 4days at 4Gy and after 120h of recovery RAPA: cells treated 
with rapamycin (10nM).  
Tubulin 
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P-p70S6K 
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The absence of the phosphorylated form of the S6K1 kinase showed that the 
mTORC1 complex was inhibited.  
 
RPE1 cell line: mTORC1 inhibition and cellular senescence 
The images of the SA-β-Gal assay performed on the RPE1 cell line are reported in 
Figure 30. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 30: SA-β-Gal assay for RPE1 cell line. Cells were treated with rapamycin and then exposed to 
γ-rays. After the end of the treatment cells were fixed and incubated with SA-β-Gal staining 
solution for ~6h. Cells were washed and then microphotographed (10X). T0: untreated control 
RL: cells treated for 4 days at 4 Gy and after 120 hours of recovery RL+R: cells treated with 
rapamycin (10nM) and irradiated 4 days at 4Gy and after 120h of recovery RAPA: control treated 
with rapamycin (10nM) 
 
Conversely from what was hypothesized, the inhibition of mTORC1 in RPE1 cell 
line did not block the activation of cellular senescence. In fact, even the cells 
treated with rapamycin before the exposure to γ-rays (indicated as RL+R) were 
positive to the β-galactosidase assay.   
As a result of the inhibition of mTORC1 a decrease of p53 and p21 expression 
was not observed (Fig.31). The increase in expression of p53 observed after γ-rays 
RPE1-T0 
RPE1-RL 
RPE1-RAPA 
RPE1-RL+R 
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treatment (RL) remains constant even in cells treated with rapamycin and 
consequently, the p21 expression is elevated in both conditions.   
 
 
 
 
 
 
 
 
 
 
Fig.31: Expression of p53 and p21 after rapamycin and γ-rays treatment. Tubulin is used as a 
loading control. T0: untreated control RL: cells treated for 4 days at 4 Gy and after 120 hours of 
recovery RL+R: cells treated with rapamycin (10nM) and irradiated 4 days at 4Gy and after 120h 
of recovery RAPA: control treated with rapamycin (10nM) 
 
The positivity to the β-galactosidase assay and the increased expression of p53 
and p21 observed in RPE1 cell line after mTORC1 inhibition demonstrated that 
mTORC1 is not able to regulate the activation of cellular senescence induced by 
genotoxic stress. 
 
RPE1 cell line: mTORC1 inhibition and mitochondrial biogenesis 
In addition to determining the effect of mTORC1 on cellular senescence, its 
effects on mitochondrial biogenesis were evaluated. 
The genotoxic stress is responsible for determining the increase in expression of 
mitochondrial proteins that take part of the respiratory complexes such as 
NDUFA9, SDHA, SDHB and of the mtDNA transcriptional factor TFAM 
(Fig.13). The expression of these proteins upon mTORC1 inhibition is reported in 
figure 32. 
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Fig. 32: Mitochondrial proteins expression after rapamycin and γ-rays treatment. T0: untreated 
control RL: cells treated for 4 days at 4 Gy and after 120 hours of recovery RL+R: cells treated 
with rapamycin (10nM) and irradiated 4 days at 4Gy and after 120h of recovery RAPA: control 
treated with rapamycin (10nM) 
 
The increase in mitochondrial proteins expression upon γ-rays treatment (RL) was 
maintained constant even if the mTORC1 complex was inhibited (RL+R).  
Taken together, the results obtained in RPE1 cell line lead us to conclude that in 
this cell line mTORC1 was not involved in the regulation of the cellular response 
to radiation treatment, nor in terms of activation of senescence nor of 
mitochondrial biogenesis.  
In figure 29 are reported the images of western blotting assay to evaluate the 
expression of the phosphorilated form of S6K1 kinase. It is possible to note that γ-
rays treatment determine the decrease expression of the active form of S6K1 
kinase, independently of mTORC1 inhibition. mTORC1 inhibition can be 
induced, in this cell line, by the activation of AMPK kinase.  
It has been shown that stimuli which induce DNA damage, could activate AMPK, 
through a p53-dependent mechanism [102,103].  
Then it has been hypothesize that in RPE1 cell line, γ-rays treatment induce 
AMPK as a consequence of DNA damage. Preliminary data indicated that in this 
cell line, γ-rays exposure induced the expression of the active form of AMPK 
(Fig. 33).  
Recently, it was shown, in skeletal muscle, that AMPK regulate mitochondrial 
biogenesis through the regulation of PGC-1α and PPARγ [177, 178].  
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It could be hypothesized that AMPK promote at least mitochondrial biogenesis 
induced after γ-rays; then the effect of AMPK inhibition on mitochondrial 
biogenesis will be investigated on RPE1 cell line treated with a specific AMPK 
inhibitor such as Compuond C.  
 
 
 
 
 
 
 
Fig.33: Expression of total and phosphorilated form of AMPK following γ-rays treatment in RPE1 
cell line determined by western blotting analysis. T0: untreated control  RL: cells irradiated f4 
days at 4Gy and after 120h of recovery.  
 
4.2.2 HCT116 and  mTORC1 
In HCT116 cell line γ-rays induced the activation of senescence and 
mitochondrial biogenesis (Fig. 12, 22, 23, 24). In order to establish the role of 
mTOR in the regulation of the response of this cell line to genotoxic stress, 
HCT116 were treated with rapamycin before the treatment with γ-rays.  
In Figure 34 the images of western blotting assay are reported through which the 
expression of the total and phosphorylated forms of the S6K1 kinase were 
evaluated. The absence of the phosphorylated form of the S6K1 kinase showed 
that the mTORC1 complex was inhibited.  
 
 
 
 
 
 
 
Fig. 34: Expression of total and phosphorilated form of S6K1 kinase. T0: untreated control  
RL:cells irradiated 3 days at 4Gy and after 120h of recovery RL+R:cells treated with rapamycin 
(10nM), irradiated 3days at 4Gy and after 120h of recovery RAPA: cells treated with rapamycin 
(10nM)  
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 HCT116 cell line: inhibition of mTORC1 and cellular senescence 
The images of the β-galalctosidase assay performed on the HCT116 cell line are 
reported in figure 35. In this cell line, even if mTORC1 was inhibited, the β-
galactosidase assay was positive, indicating that the cellular senescence induced 
by genotoxic stress in HCT116 is not regulated by mTORC1. The evaluation of 
cellular morphology confirmed that the inhibition of mTORC1 does not affect the 
cellular response to γ-rays treatment; the cells increased in size and the 
cytoplasmic vacuoles were present, all morphological changes typical of HCT116 
senescent cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 35: SA-β-Gal assay for HCT116 cell line: cells were treated with rapamycin (10nM) and then 
expose to γ-rays treatment. Cells were therefore fixed and incubated with SA-β-Gal staining 
solution for 6h. Cells were washed and then microphotographed. T0: untreated control RL: cells 
treated for 3 days at 4 Gy and after 120 hours of recovery RL+R: cells treated with rapamycin 
(10nM) and irradiated 3 days at 4Gy and after 120h of recovery RAPA: control treated with 
rapamycin (10nM) 
 
The induction of senescence in this cell line after genotoxic stress was 
accompanied by the increase in p53 and p21 expression , which were responsible 
for the proliferative block observed in this cell line (Fig.24). As the mTORC1 
inhibition did not cause the blocking of senescence it should not have effect on the 
HCT116-RAPA HCT116-T0 
HCT116-RL HCT116-RL+R 
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expression of p53 and p21. Indeed, the increase in p21 expression was observed 
as a consequence of γ-rays treatment despite mTORC1 was inhibited (Figure 36).   
 
 
 
 
 
 
Fig.36: p21 expression after rapamycin and radiation treatment in HCT116 cell line. Tubulin were 
used as a loading control. T0: untreated control RL: cells treated for 3days at 4 Gy and after 120 
hours of recovery RL+R: cells treated with rapamycin (10nM) and irradiated 3 days at 4Gy and 
after 120h of recovery RAPA: control treated with rapamycin (10nM) 
 
Taken together, these results showed that in HCT116 cell line the inhibition of 
mTORC1 was not able to block the activation of cellular senescence upon 
genotoxic stress. 
 
HCT116 cell line: inhibition of mTORC1 and mitochondrial biogenesis. 
Next, the effect of mTORC1 inhibition on  mitochondrial biogenesis was 
determined upon genotoxic stress in HCT116 cell line. It was previously shown 
that the treatment of HCT116 cell line with γ-rays induced the increase in 
expression of some proteins of respiratory complexes (NDUFA9, SDHA and 
SDHB) and of TFAM (Fig.12). In order to determine the effect of mTORC1 
inhibition on mitochondrial biogenesis variations of expression of these proteins 
were evaluated (Fig.37). 
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Fig.37: Mitochondrial proteins expression after rapamycin and γ-rays treatment T0: untreated 
control RL: cells treated for 4 days at 4 Gy and after 120 hours of recovery RL+R: cells treated 
with rapamycin (10nM) and irradiated 4 days at 4Gy and after 120h of recovery RAPA: control 
treated with rapamycin (10nM) 
 
The increase expression of mitochondrial proteins NDUFA, SDHA, SDHB, 
ATPase5B and TFAM induced after γ-rays treatment (RL) remained unchanged 
after inhibition of mTORC1 (RL+R). This result demonstrated that mTORC1 
inhibition is not implicated in the response of this cell line to irradiation. In fact, 
the rapamycin treatment did not block the activation of mitochondrial biogenesis 
observed in this cell line.  
Therefore, it may be concluded that mTORC1 does not control the activation of 
senescence and mitochondrial biogenesis induced by genotoxic stress in HCT116. 
However, conversely from what was seen in RPE1, in HCT116 cell lines the 
phosphorylated form of S6K1 kinase was maintained after γ-rays treatment. 
Further studies are needed in order to clarify the molecular pathways activated 
after radiation treatment which could regulate the induction of both senescence 
and mitochondrial biogenesis. The involvement of AMPK kinase that may be 
activated in a p53-dependent manner could be a valid hypothesis.  
 
4.2.3 XTC.UC1 and  mTORC1 
The XTC.UC1 cell line responds to genotoxic stress by inducing cellular 
senescence (Fig.25, 26), but γ-rays treatment not induced an increase of 
mitochondrial biogenesis (Fig. 38). As reported in figure 38, no change in proteins 
expression were observed. This is because XTC.UC1 is a model of oncocytic 
tumor, and then is characterized by a basal mitochondrial hyperproliferation. The 
transcriptional factors and the co-activator of mitochondrial biogenesis, as well as 
protein synthesis, are in this cell line iperactivated.  
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Fig.38: Mitochondrial proteins expression in XTC.UC1 cell line after γ treatment. Tubulin is used 
as a loading control. T0: untreated control IR4: cells irradiated 4 adys at4Gy 
 
The response of this cell line to mTORC1 inhibition is evaluated, either in terms 
of senescence or mitochondrial biogenesis.  
Western blotting assay by which the expression of the phosphorilated and total 
forms of S6K1 kinase were determined is presented in figure 39. The absence of 
the phosphorilated form of the kinase demonstrated that the rapamycin treatment 
has determined the inhibition of mTORC1.  
 
 
 
 
 
 
 
Fig. 39: Expression of total and phosphorilated form of S6K1 kinase. T0: untreated control  
RL:cells irradiated 4 days at 4Gy and after 120h of recovery RL+R:cells treated with rapamycin 
(10nM), irradiated 4days at 4Gy and after 120h of recovery RAPA: cells treated with rapamycin 
(10nM)  
 
An interesting data that emerges from the evaluation of the phosphorylated form 
of S6K1 kinase is the increase expression of the active form of this kinase 
following exposure to γ-rays (RL), which shows that genotoxic stress determines, 
in this cell line, the activation of mTORC1. This result supports the hypothesis 
that mTORC1 regulate the response of this cell line to genotoxic stress at least in 
terms of activation of cellular senescence.  
 
XTC.UC1 cell line: mTORC1 inhibition and cellular senescence  
The SA-β-Gal assay of the XTC.UC1 cell line is shown in figure 40. 
Unlike what has been observed in other cell lines, inhibition of mTORC1 is 
responsible for blocking the activation of cellular senescence. In fact XTC.UC1 
treated with rapamycin before exposure to γ-rays (RL+R) are negative to the β-
galactosidase assay unlike the XTC.UC1 cell line treated only with γ-rays (RL).  
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The observation of cellular morphology confirms the data obtained by β-
galactosidase assay. In fact, after mTORC1 inhibition, the cells does not increase 
in size and is not possible to observe the appearance of cytoplasmic vacuoles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.40: Sa-β-Gal assay for XTC.UC1 cell line: cells are treated with rapamycin (10nM) and then 
irradiated. After the end of the treatment cells were fixed and incubated with SA-β-Gal staining 
solution for ~6h. Cells were washed and then microphotographed (10X) T0: untreated control RL: 
cells treated for 4 days at 4 Gy and after 120 hours of recovery RL+R: cells treated with 
rapamycin (10nM) and irradiated 4 days at 4Gy and after 120h of recovery RAPA: control treated 
with rapamycin (10nM) 
 
In order to determine whether mTORC1 act by inhibiting the increase of p21, 
observed in XTC.UC1 cell line after γ-rays treatment and that is involved in the 
senescence activation, changes in p21 expression was evaluated by western 
XTC.UC1-T0 
XTC.UC1-RL XTC.UC1-RL+R 
XTC.UC1-RAPA 
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blotting (Fig.41). The mTORC1 inhibition determines a decrease of p21 
expression reaching levels close to those of non-irradiated control (T0).  
 
 
 
 
 
 
 
Fig.41: p21 expression after rapamycin and γ-rays treatment. T0: untreated control RL: cells 
treated for 4 days at 4 Gy and after 120 hours of recovery RL+R: cells treated with rapamycin 
(10nM) and irradiated 4 days at 4Gy and after 120h of recovery RAPA: control treated with 
rapamycin (10nM) 
 
XTC.UC1 cell line: inhibition of mTORC1 and mitochondrial biogenesis 
Genotoxic stress seems not induce the activation of mitochondrial biogenesis in 
XTC.UC1 cell line (Fig. 38). It is plausible suppose that a slightly increase in 
mitochondrial biogenesis was induced in this cell line, but it is difficult to 
determine as a consequence of the  mitochondrial hyperproliferation characteristic 
of this line. To verify this hypothesis, the effect of mTORC1 inhibition on 
mitochondrial biogenesis was evaluated.   
Therefore, the expression of some mitochondrial proteins (NDUFA), SDHA; 
SDHB, ATPase5B and TFAM) after mTORC1 pharmacological inhibition and γ-
rays treatment was evaluated.  
Unlike the hypothesis, it was no observed a decrease expression of mitochondrial 
proteins after the combined treatment (Fig. 42).  
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Fig.42: Western blotting relativo all‟espressione delle proteine mitocondriali T0:controllo non 
trattato  RL: cellule irradiate 4 giorni a 4Gy e lasciate 120h in recupero RL+R: cellule trattate con 
rapamicina (10 nM), irradiate 4 giorni a 4Gy e lasciate 120 h in recupero RAPA: controllo trattato 
con rapamicina (10nM)  
 
These results lead us to conclude that γ-rays treatment did not induce a further 
increase in mitochondrial biogenesis in XTC.UC1 cell line. The most interesting 
data that emerges in this study is that senescence observed in XTC.UC1 cell line 
after exposure to a genotoxic stress is blocked after inhibition of mTORC1. 
Therefore it is possible to conclude that mTORC1 is a regulator of senescence 
induce in this cell line.  
 
 
 
In the first part of this study it has been demonstrated that in RPE1 and HCT116 
cell line genotoxic stress induced the activation of mitochondrial biogenesis and 
senescence. Further studies will be then conducted in these cell lines to evaluate if 
mitochondrial biogenesis will be involved in the activation of senescence.  
In these cell line has been shown that mTORC1 is not involved in regulation of 
senescence and mitochondrial biogenesis, and it was hypothesized a role for 
AMPK. Then experiments to evaluate the  effect of AMPK inhibition will be 
conducted.  
The response of XTC.UC1 cell line subjected to treatment with γ-rays has 
demonstrated the involvement of mitochondrial dysfunction caused by mtDNA 
mutations in the maintenance of senescence induced by genotoxic stress. Based on 
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the experiments conducted seem that ROS production is directly involved in the 
regulation of senescence. In this cell line it was also demonstrated that mTORC1 
inhibition is responsible to block the activation of senescence.  
 
4.3 mTOR AND THE ONCOCYTIC TUMORS OF THE HEREDITARY CANCER SYNDROME  
The previous part of this study  has demonstrated the involvement of mTORC1 in 
the regulation of senescence induced  by γ-rays treatment in XTC.UC1 cell line; 
the results obtained in RPE1 and HCT116 cell line, have ruled out the 
involvement of mTOR in the regulation of mitochondrial biogenesis following γ-
rays treatment.  
XTC.UC1 cell line is characterized by an aberrant mitochondrial hyperplasia that 
is not increased by genotoxic stress exposure (Fig.38). This result is expected as  
this cell line is a model of oncocytoma and is characterized by a constitutive 
activation of mitochondrial replication and protein synthesis.  
As previously discuss, it has been reported that mTORC1 regulates mitochondrial 
metabolism [132] by interacting with and activating the transcriptional factor YY1 
and PGC-1α.  
It has been suggested that the stimulation of mitochondrial biogenesis, which 
characterizes XTC.UC1 cell line, could be sustained by a nuclear factor namely  a 
tumor suppressor gene inactivation, which lead to activation of mTORC1.  
This hypothesis is based on the fact  that XTC.UC1 represent the in vitro model of 
what occurs in vivo in patients affected by two hereditary cancer syndrome: 
Cowden syndrome (CS) [145] and Birt-Hogg-Dubé syndrome (BHD) [153].   
Patients affected by  these syndromes show similar cutaneous manifestations and 
are predisposed to the development of multiple tumors that in some cases may be 
oncocytic. BHD and CS patients develop rarely oncocytic tumors which mainly 
occur in the kidney and the thyroid respectively. The cause of oncocytic 
transformation associated to inherited tumor syndromes has not been elucidated.  
It has been hypothesized that the activation of mTORC1 pathway could induce  
mitochondrial biogenesis and then lead to the oncocytic transformation in this 
patients. This hypothesis was formulated according to the function of the main 
causative genes of these two syndromes: namely PTEN for CS patients [147] and 
FLCN for BHD [153]. PTEN acts as a negative regulator of mTOR as a 
consequence of its inhibition of AKT [150];  FLCN function is yet to be 
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elucidated but it has been hypothesized that FLCN could act as a negative 
regulator upstream mTORC1 pathway as a consequence of its interaction with 
AMPK, that mimicking TSC1/TSC2 complex function [155]. 
We  hypothesized that PTEN and FLCN could exert their functions in a common 
pathway, which when deregulated may cause mTOR activation, subsequent 
increase of PGC-1α and mitochondrial biogenesis.  
The study of oncocytomas associated to CS and BHD suggested that PTEN/ 
FLCN double heterozigosity could cause the oncocytic transformation in inherited 
syndromes. 
Indeed the analysis of thyroid oncocitoma developed by a CS patient come to the 
attention of the unit of medical genetics, has demonstrated the loss of one of the 
two alleles of PTEN; causative event in the development of pathology, and a 
deletion of 242bp in respiratory complex I subunit ND1. Also it has been verified 
the loss of one FLCN allele in thyroid oncocytomas [179]. 
In the meantime, a BHD patient, who developed a rare parotid oncocytic tumors, 
was also analyzed. First, direct sequencing of FLCN resulted in the discovery of a 
germline heterozygous mutation, namely c.347dupA. The subsequent analysis of 
the pathologic tissue did not show loss of the wild-type FLCN allele. The 
oncocytic tumor was then characterized by UPL for PTEN deletion. The analysis 
demonstrated the loss of one PTEN allele (Fig.43) compared to DNA extracted 
from peripheral blood of two different healthy controls. 
 
 
Fig.43: Copy number assay using UPL showing loss of one PTEN allele in the oncocytic lesion of  
BHD patient compared to the medium of two healthy controls. 
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These results revealed the existence of a “mirrored” molecular profile in the BHD 
and the CS patients‟ oncocytic tumors and suggested that the two syndromes may 
be related and that FLCN and PTEN probably converge in a common pathway 
leading to oncocytic phenotype. 
In order to verify if mutations, deletions or  PTEN /FLCN  double heterozigosity 
could be responsible of mitochondrial biogenesis activation through the regulation 
of PGC-1α expression, experiments of complementation of FLCN and PTEN in 
XTC.UC1, the most suitable in vitro model, were carried out.  
This cell line is resulted the most suitable in vitro model to verify our hypothesis; 
in fact do not express PTEN (as resulted by the sequencing conducted in the first 
part of this thesis), and furthermore was characterized for the loss of one allele of 
FLCN as verified by UPL copy number assay (Fig. 44). 
 
 
 
 
 
 
 
 
 
 
Fig. 44:  Copy number assay by UPL technique for FLCN which shows XTC.UC1 monoallelic 
expression. 
  
We performed a specific semi-quantitative PCR and RT-PCR experiment 
comparing XTC.UC1 PGC-1α expression to the expression in HEK293, HPS11 
and RPE1 cell lines. Semi-quantitative PCR shows an increase of  PGC-1α  
expression in XTC.UC1 cell line  compared to the other cell lines (Fig.45).  
This data was confirmed by quantitative real time PCR (qRT-PCR) which 
compared PGC-1α expression XTC.UC1 cell line to its expression in  HPS11. 
HPS11 was selected as a control for PGC1a expression as it is one of the rare cell 
lines which shows a detectable PGC-1α expression at basal conditions (Fig. 45). 
The qRT-PCR experiment showed a thirty-fold increase of PGC-1α expression in 
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XTC.UC1 compared to HPS11. In order to verify if the increase of PGC-1α 
expression level was accompanied by the increase of its co-activators, namely 
PGC-1β and PRC, expression levels of these co-activators were measured in 
XTC.UC1 cell line.  The experiment has showed not differences in  the expression 
of PGC-1β and PRC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 45: A: Semi-quantitative real time PCR for PGC-1α (above) in different cells normalized on 
tubulin expression (below) B:qRT-PCR for PGC-1α, PGC-1β and PRC expression in XTC.UC1 
and HPS11 cell lines.  
 
All these findings support the hypothesis that mitochondrial biogenesis can be 
regulate by PTEN and FLCN, and suggest that the consequent deregulation of 
mTOR pathway could  lead to the activation of mitochondrial biogenesis through 
the regulation of PGC-1α expression.  
To investigate the effect of PTEN and/or FLCN restored expression on PGC-1α 
transcription the two genes are complemented in XTC.UC1 cell line. 
To this aim we have cloned both PTEN full lenght cDNA and FLCN full lenght 
cDNA into two plasmid vectors, namely pcDNA 3.1 (-) PURO and pcDNA 3.1 
(+)ZEO.  
First, we have investigate the effect of PTEN complementation. 
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PTEN expression was verified by western blotting (Fig. 46) which demonstrated 
the presence, in XTC.UC1 cell line transfected with PTEN expressing vector, of a 
band comparable in intensity  to that of  RPE1 cell line, used as a positive control.  
 
 
 
 
 
 
 
 
 
Fig.46: Western blotting for PTEN expression on XTC.UC1 cell line after PTEN 
complementation. 
  
The effect of PTEN complementation on PGC-1α expression were verified by 
qRT-PCR. In figure 47 are reported PGC-1α expression of PTEN-transfected 
XTC.UC1 (PTEN) and mock-trasfected XTC.UC1 (PURO).  
 
 
 
 
 
 
 
 
 
 
Fig.47: qRT-PCR for the evaluation of PGC-1α expression on XTC.UC1 cell line after PTEN 
complementation. 
  
It was observed a slightly increase of  PGC-1α expression level after restoration of 
PTEN expression. As  the sample analyzed was too small and  the data are not 
statistically significant, they should be confirmed on a larger set.  
This result seems to disagree with the hypothesis that PTEN expression, resulting 
in mTOR inhibition, should reduce PGC-1α expression and arrest mitochondrial 
biogenesis.  
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As the role of PTEN as an inhibitor of mTORC1 has been demonstrated it was 
expected that  PTEN restored expression should inhibit mTORC1 activation.  
In order to establish if PTEN is functionally active, the expression of the 
phosphorilated and total form of S6K1 kinase was evaluated. The decrease 
expression of phosphorilated S6K1 after PTEN restored expression, shows that 
the protein is active and therefore able to inhibit mTORC1 complex (Fig. 48). 
 
 
 
 
 
 
 
Fig.48: Expression of the total and phosphorilated form of S6K1 kinase in XTC.Uc1 cell line after 
PTEN complementation. Action is used as normalization gene 
 
The presence of a week band of the phosphorilated form of S6K1 indicates that 
mTORC1 is not completely inhibited by PTEN expression.  
However a possible explanation of this apparent contradictory result could be 
justified by the fact that these experiments were carried out on XTC.UC1 cell line 
which has been complemented only  for PTEN expression  but not for FLCN. 
It could be speculated that a compensatory signal is activated and is responsible to 
keep  PGC-1α expression level up-regulated.  
It was hypothesized that PTEN expression induced a slightly increase of PGC-1α 
expression as a consequence of the induction of a compensatory signal. Therefore 
the expression of genes controlled by  YY1-PGC-1α, that is inhibited in absence 
of mTORC1, was evaluated.  
Preliminary experiments demonstrated that PTEN expression induced a slightly 
increase in the expression of two mitochondrial proteins namely Porin and TFAM 
(Fig. 49). This result, which should be confirmed even by evaluation of 
expression of the other regulator of mitochondrial biogenesis (for example NRF1 
and PGC-1β), supports the result obtained by PTEN complementation. 
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Fig. 49: Expression of TFAM and Porin after PTEN complementation. Tubulin is used as 
housekeeping gene for normalization. 
 
In order to confirm the data obtained after PTEN restored expression, XTC.UC1 
cell line was treated with rapamycin, a specific inhibitor of mTORC1.  
Figure 50 are shows the western blotting assay to evaluate the efficiency of 
mTORC1 inhibition. Subsequently the expression of PGC-1α was evaluated by 
qRT-PCR (Fig.51). 
 
 
 
 
 
 
 
Fig.50: Pharmacological inhibition of mTORC1 through rapamycin treatment. 
 
  
 
 
 
 
 
 
 
 
Fig.51: PGC-1α expression in XTC.UC1 cell line after rapamycin traetment (10nM). 
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mTORC1 inhibition induces a slightly increase of PGC-1α expression, 
comparable to the data obtained after PTEN restored expression. 
These results seems to rule out the function of PTEN as  a negative regulator of 
PGC-1α through mTORC1 repression. A possible explanation on this apparent 
contradictory result is that we have restored only PTEN expression but not FLCN, 
while the initial hypothesis is that PTEN and FLCN double heterozigous leads to 
PGC-1α expression. Stable clones in which both PTEN and FLCN expression will 
be restored should give a complete idea of the role of these two tumor suppressor 
genes on PGC-1α expression through mTORC1 pathway.   
Finally, the effects of FLCN restored expression on the regulation of PGC-1α 
were evaluated. FLCN expression were initially evaluated by western blotting 
analysis (Fig.52). 
 
 
 
 
 
 
 
Fig.52:  Western blotting for FLCN expression in XTC.UC1 cell line complemented with FLCN . 
Western blotting assay was performed using an anti-myc antibody  
 
Figure 53 reports PGC-1α expression level determined by qRT-PCR on mock 
transfected XTC.UC1 and FLCN-transfected XTC.UC1.  
 
 
 
 
 
 
 
 
 
 
Fig. 53: PGC-1α expression after FLCN restored expression. 
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FLCN restored expression induced a slightly decrease of PGC-1α expression level 
in XTC.UC1 cell line, which should be confirmed increasing the number of 
samples analyzed and  in stable clones expressing both FLCN and PTEN. 
This result seems to demonstrate that FLCN is involved in PGC-1α expression, 
but the previously data seems to shown that mTORC1 is not involved in PGC-1α 
expression. Then, the pathway that links FLCN to PGC-1α is yet to be elucidated.  
FLCN interacts with AMPK [155-158], and recently it has been demonstrated that 
AMPK should regulate mitochondrial genes expression [177-178]. It is possible to 
speculate that AMPK is involved in the regulation of PGC-1α and then in that of 
mitochondrial biogenesis. The role of AMPK in the  regulation of mitochondrial 
biogenesis will be investigated by the use of specific AMPK inhibitors such as 
Compound C. 
As previously discuss, before to rule out the involvement of PTEN and mTORC1 
in the regulation of PGC-1α expression, stable clones in which both PTEN and 
FLCN expression will be restored should give a complete idea of the role of these 
two tumor suppressor genes on PGC-1α expression through mTORC1 pathway.   
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5. DISCUSSION 
 
Radiotherapy, as well as chemotherapeutic agents, can induce the activation of 
cellular senescence in tumoral tissue [52, 53]. Senescence is considered, like 
apoptosis, an efficient mechanism that cells activate in order to limit tumor 
growth [70]. Several reports indicate that some molecules secreted by senescent 
cells could stimulate the immune system that is responsible for their elimination 
[70]. These data supported the idea of activating senescence as the treatment of 
cancer patients. In fact, various therapeutic studies are currently under 
development, directed to activate cellular senescence based on the use of 
molecules that act by enhancing senescence-related pathways [2, 47]. Moreover, 
in order to enhance treatment effectiveness, therapeutic protocols involving the 
use of these molecules in combination with standard procedures, such as 
radiotherapy and chemiotherapy, are in phase of research.  
On the other hand, several reports have demonstrated an increase of mtDNA copy 
number after radiation treatment in certain tissues of γ-irradiated mice [167,168]. 
Moreover, experimental data show that patients, affected by colon cancer, 
following radiation treatment, may develop tumor relapses with oncocytic features 
[169, 170]. Recently, the increase of mitochondrial biogenesis, ROS accumulation 
and decrease of ATP synthesis have been demonstrated as  effectory pathways of 
H-Ras induced senescence [25]. It was therefore hypothesized that the activation 
of mitochondrial biogenesis and thus the differentiation towards an oncocytic 
phenotype observed after γ-rays treatment may be involved in the activation of 
cellular senescence.  
Taken together, the data obtained in this study allow us to conclude that, in our 
cellular models, genotoxic stress induced activation of mitochondrial biogenesis 
and senescence.  It is not possible to establish whether mitochondrial biogenesis is 
activated before senescence or if it is one of senescence-related consequences. 
Therefore, further experiments must be carried out in order to determine if 
inhibition of mitochondrial biogenesis could affect the activation of cellular 
senescence.  
The most interesting result that emerges from this study concerns the oncocytic 
model XTC.UC1. It has been demonstrated that in this cell line the genotoxic 
stress is able to determine the activation of cellular senescence and that the 
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mitochondrial dysfunction, typical of this cell line, contributes to the maintenance 
of senescent phenotype.  
The involvement of mitochondrial dysfunction in senescence had already been 
hypothesized by the group of Moiseva in fibroblasts that underwent H-Ras 
induced senescence, through pharmacological inhibition of complexes I and III 
and by RNA-interference experiments [25]. The results obtained in this study 
demonstrated that mtDNA mutations leading to mitochondrial dysfunction 
contribute to senescence phenotype in γ-rays induced senescence. 
The increase of ROS production and the increase in antioxidant enzyme 
expression observed in XTC.UC1 cell line following γ-rays treatment, 
demonstrated that mitochondrial dysfunction contributes to the maintenance of 
senescent phenotype through oxidative stress. In fact, ROS causing DNA damage, 
are responsible for maintenance active DDR that is involved in the activation of 
this type of senescence.    
Furthermore, it was shown that the molecular pathway regulating the response of 
the oncocytic model to γ-rays treatment is different from the pathway that is 
activated in the other cell lines. The involvement of mTOR and in particular of 
mTORC1 has been shown responsible for determining senescent phenotype in 
XTC.UC1 cell line. In fact, mTORC1 inhibition in this cell line prevents the 
activation of cellular senescence, while the same inhibition did not have any 
effects on senescence process in  the other cell lines.  
The difference in senescent response of XTC.UC1 compared to the other cell lines 
analyzed in this study can be attributed mainly to the presence of TP53 mutations. 
Preliminary data have shown that in RPE1 cell lines, which do not bear TP53 
mutations, γ-rays treatment induced the activation of AMPK kinase which inhibits 
mTOR. Consequently, AMPK activation observed in this cell line justifies the 
finding that mTORC1 is not responsible for regulating the response of these cell 
lines to radiation treatment.   
AMPK activation following γ-rays treatment has already been demonstrated 
[181], and it has been verified that this kinase is activated in a p53-dependent 
mechanism [181]. Therefore, due to the presence of TP53 mutations, genotoxic 
stress can not induce AMPK activation in XTC.UC1 cell line. Moreover, it has 
been demonstrated that γ-rays are responsible to activate mTORC1 in oncocytic 
cell line, which is already active in basal conditions, due to the loss of PTEN.  
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It has been shown that cells carrying mutations in ND5 gene which codify for one 
subunit of respiratory complex I are characterized by activation of AKT pathway, 
compared to control cells with wild-type protein [182] 
The recovery of complex I functionality, achieved after introducing a yeast 
NADH quinone oxidoreductase (NDI1) gene led to a decrease in the 
phosphorilation of AKT. According to the authors, AKT activation depends on 
ROS production [182]. It is possible to hypothesize that in XTC.UC1 cell line, 
where mTORC1 complex is already active as a consequence of PTEN loss, the 
mitochondrial dysfunction contributes to activation of mTORC1 observed 
following γ-rays treatment, probably due to enhanced AKT activation induced by 
increased ROS production.  
Thus, mitochondrial dysfunction could contribute to the maintenance of senescent 
phenotype acting by a dual mechanism that involves ROS. ROS produced 
following γ-rays treatment may be responsible to amplify the DDR and on the 
other hand contribute to mTORC1 activation that seems directly responsible, in 
this cell line, to control cellular senescence.   
In order to demonstrate the involvement of mitochondrial dysfunction in 
regulating cellular senescence, HXTC-UC1 cybrid cell line were subjected to 
treatment with γ-rays. This cell line was obtained from the fusion of enucleated 
XTC.UC1 which served as a donor of cytoplasm, and 143B TK-osteosarcoma cell 
line deprived of their mtDNA (Rho0), as nuclei donor.     
If mitochondrial dysfunction is a general mechanism responsible for control of γ-
rays induced senescence, genotoxic stress should activate senescence pathway in 
HXTC.UC1 cell line as well.  
Oncocytic tumors have been well characterized in the laboratory of Medical 
Genetics directed by Prof. Romeo, where it was demonstrated that these tumors 
are in most cases benign, having  a low proliferative potential and are not 
aggressive [135, 138-144].  Furthermore, in these tumors the presence of 
mutations in respiratory complex I is associated to a destabilization of HIF-1α 
(Hypoxia-inducible factor) which is responsible for mediating the metabolic 
adaptation of cells during the progression from benignity towards malignancy. 
Even in hypoxic condition mitochondrial dysfunction determines HIF-1α 
destabilization as a consequence of the increase ratio of α-ketoglutarate/succinate 
[140]. Taken together, these data demonstrated that the presence of complex I 
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disruptive mutations in mtDNA contributes to tumor growth reduction and to 
maintainance of benign state of the  tumors [138].  
The data obtained by this study lead us to speculate that the low proliferative 
potential of oncocytoma could be attributed to activation of cellular senescence, 
and  if senescence is activated in oncocytoma this may depend on mitochondrial 
dysfunction. XTC.UC1 cell line is characterized by the presence of TP53 
mutations and complete absence of PTEN. It will be therefore necessary to 
sequence both genes in a panel of oncocytic tumors to investigate the potential 
occurrence of mutations. This data will allow verification that the oncocytoma-
related senescence is activated following the pattern described in XTC.UC1.  
In the second part of this study it has been verified the involvement of mTORC1 
in the regulation of PGC-1α expression. This experiment has been conducted in 
order to verify which mechanism induce the development of oncocytoma in 
patients affected by two hereditary familial syndrome, CS syndrome and BHD 
syndrome. The study of CS and BHD patients lead us to hypothesized that the 
double heterozigous of the two tumor suppressor genes causative of the 
syndromes, respectively PTEN and FLCN, leads to mitochondrial biogenesis 
activation through the involvement of mTORC1. The XTC.UC1 cell line was 
used as model to verify the hypothesis because do not express PTEN and is 
characterized by loss of one FLCN allele.  Taken together the results obtained in 
XTC.UC1 cell line seem to indicate that mTOR is not involved in the regulation 
of PGC-1α expression. This result it has been demonstrated after 
complementation of PTEN and after pharmacological treatment of XTC.UC1 cell 
line with rapamycin, a specific inhibitor of mTORC1. In contrast with what 
hypothesized, the results of these experiments seem to demonstrate that mTORC1 
acts in cells as an inhibitor of  mitochondrial biogenesis as the increase of PGC-1α 
expression was observed after inhibition of mTORC1.  
Further studies will be conducted in order to demonstrate if mTORC1 activation 
leads to inhibition of mitochondrial biogenesis, even in XTC.UC1 which stably 
express PTEN.  
The experiments of reciprocal complementation of FLCN and PTEN in XTC.UC1 
indicated that the two genes have two opposite functions. While PTEN expression 
induced a slightly increase of PGC-1α expression, a decrease of PGC-1α was 
observed in cells complemented with FLCN. PTEN acts as a negative regulator of 
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mTORC1. Thus, it can be assumed that if mTORC1 is not involved in regulating 
mitochondrial biogenesis, PTEN loss is not involved in regulating PGC-1α 
expression through mTORC1.                                                                                                                                    
At the same time, FLCN should not act through mTORC1 in regulating PGC-1α 
expression.  
The role of FLCN as an inhibitor of mTORC1 has been deduced on the basis on 
the functions of its interactors FNIP1 and FNIP2, which also interact with AMPK  
that inhibits mTORC1 [155-158].  It may be speculated that FLCN acts regulating 
PGC-1α expression through AMPK. In fact, it has been demonstrated in skeletal 
muscle, that AMPK regulates mitochondrial biogenesis through controlling PGC-
1α and PPARγ expression [177, 178]. 
The hypothesis of AMPK involvement in regulation of mitochondrial biogenesis 
is in apparent disagreement with the basal activation of mTORC1 observed in 
XTC.UC1. Further studies will be conducted in order to establish how loss of 
FLCN and PTEN may control mitochondrial biogenesis, and to elucidate the 
pathway that links FLCN to PGC-1α. It is also needed to verify whether the 
increased expression of PGC-1α observed after PTEN complementation can be 
attributed to the activation of a compensatory mechanism.  
It was initially hypothesized that it was FLCN and PTEN double heterozigous to 
induce mTORC1 activation and then mitochondrial biogenesis. The study 
presented in this thesis are conducted on XTC.UC1 cell line complemented with 
FLCN or PTEN and before ruling out the involvement of PTEN and mTOR in 
regulation of mitochondrial biogenesis, it will be necessary to generate stable 
clones which are complemented with PTEN and FLCN in order to verify the 
effect of the double heterozygous on mTOR and PGC-1α expression.   
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6. CONCLUSIONS 
 
The results obtained in the first part of this thesis, allowed us to demonstrate that 
exposure to genotoxic stress is responsible for activating cellular senescence in 
oncocytic model. Based on these results, it has been speculated that senescence 
induced in this cell line is supported by the presence of mitochondrial 
dysfunction. Mitochondrial dysfunction contributes to the maintenance of 
senescence phenotype through the constant production of ROS.  
It was also demonstrated that in XTC.UC1 cell lines mTOR, and in particular 
mTORC1 is responsible to regulate the activation of cellular senescence, in 
contrast to what observed in other cell lines.   
This study‟s results, together with data from literature, lead us to hypothesize that 
ROS produced following γ-rays treatment are on the one hand responsible for 
keeping the DDR, directly involved in inducing senescence, active. On the other 
hand, they contribute to mTORC1 activation that is shown to regulate cellular 
senescence in this cell line. 
These data lead us to speculate on what happens in vivo in oncocytoma. These 
tumors are benign and have a low proliferative potential. On the basis of data 
observed in XTC.UC1 cell line, it is possible to conclude that the typical benign 
state of oncocytoma is imputable to the activation of cellular senescence, which 
blocks proliferation. It is possible to hypothesize that senescence is activated in 
oncocytoma  through a mechanism that involves mitochondrial dysfunction.  
In the second part of this thesis we have investigated the role of mTORC1 in 
sustaining the activation of mitochondrial biogenesis that characterizes XTC.UC1 
cell line. Exploring this question allows us to understand if loss of tumor 
suppressor gene can determines the development of oncocytomas in CS and BHD 
patients.  
Unlike literature data, the results obtained seem to exclude the involvement of 
mTOR in regulating PGC-1α expression, and instead suggest that mTOR acts as a 
PGC-1α inhibitor.  
Besides, PTEN and FLCN complementation experiments seem to indicate that the 
two genes have opposite functions in regulating PGC-1α expression. In fact, 
PTEN complementation determines an increase in PGC-1α expression, while 
FLCN reconstruction seems to lead to a decrease in PGC-1α expression. The 
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initial hypothesis of this study was that PTEN and FLCN double heterozigous are 
responsible for sustaining PGC-1α expression. Additional studies will be therefore 
conducted to investigate more closely the effect of PTEN and FLCN restore 
expression on PGC-1α and to evaluate  the involvement of mTORC1. 
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APPENDIX A 
 
 
 
PRIMER REAL TIME 
 
GENE PRIMER FW PRIMER RV 
PGC-1α 5‟-TGAGAGGGCCAAGCAAAG-3‟ 5‟-ATAAATCACACGGCGCTCTT-3‟ 
TUBULINA 5‟ATACCTTGAGGCGCAAAA-3‟ 5‟-CTGATCACCTCCCAGAACTTG-3‟ 
 
 
PRIMER RT 
 
GENE PRIMER FW PRIMER RV 
PGC-1α 5‟-TTGCCCAGATCTTCCTGAAC-3‟ 5‟-AAATGAGGGCAATCCGTCTT-3‟ 
TUBULINA 5‟-GAACGTGATGGTGTCCACAG-3‟ 5‟-CGCTTACGCAGCTTGTCATA-3‟ 
 
 
PRIMER PTEN (MgCl2: 2.5mM- Fast Start Taq (Roche)) 
 
 PRIMER FW PRIMER RV 
Promoter 5‟-GCGTGGTCACCTGGTCCTTT-3‟ 5‟-GCTGCTCACAGGCGCTGA-3‟ 
Exon 1 5‟-AAGTTTGAGAGTTGAGCCG-3‟ 5‟-GTGTTGGAGGCAGTAGAA 
Exon 1a 5‟-ATTTCCAGGGCTGGGAA-3‟ 5‟-GAAAGGTAAAGAGGAGCA-3‟ 
Exon 2 5‟-TGTCTTTTCAGGCAGGTGTC-3‟ 5‟-GGTGACCAGCATTTTATGGAC-3‟ 
Exon 3 5‟-TTTGATGGGAAAATGATGTCTG-3‟ 5‟-CATGAATCTGCCAACAATG-3‟ 
Exon 4 5‟-GCATGGAAGCACCTGAATTTAC-3‟ 5‟-TGTTTCTCCCTGTGATTGC-3‟ 
Exon 5 5‟-TTGCATTGAGAGTCCTGACG-3‟ 5‟-AAGAAACCCAAAATCTGTTTTCC-3‟ 
Exon 6 5‟-GCATAGCTGTAGGGCAGAGG-3‟ 5‟-TTGGCTTCTTTAGCCCAATG-3‟ 
Exon 7 5‟-TCAAGATTGCAGATACAGAATCC-3‟ 5‟-GGCCTTTTCCTTCAAACAGG-3‟ 
Exon 8 5‟-TGTCATTTCATTTCTTTTTCT-3‟ 5‟-TCAAGCAAGTTCTTCATCCAGC-3‟ 
Exon 9 5‟-TGTTCATCTGCAAAATGGAATAA-3‟ 5‟-GGTAATCTGACACAATGTCC-3‟ 
 
 
Temperatur Time Cycle 
95°C 5 min 1 
96°C 30 sec  
35 58°C 30 sec 
72°C 1 min 
72°C 7 min 1 
 
 
 
PRIMER K-Ras (MgCl2: 1.5mM-Fast Start Taq (Roche)) 
 
 PRIMER FW PRIMER RV 
Exon 1 5‟-TATTAAAAGGTACTGGTGG-3‟ 5‟-ATAAGTACTCATGAAAATGG-3‟ 
Exon 2 5‟-AACAATGTCTTTTCAAGTCC-3‟ 5‟-TGGCATTAGCAAAGACTC-3‟ 
Exon 3 5‟-TACATTGTTTTCTTTCAGCC-3‟ 5‟-TAGTATAGCATAATTGAGAG-3‟ 
Exon 4a 5‟-TCATAATCTCAAACTTCTTG-3‟ 5‟-AAGTAGTTCTAAAGTGGTTG-3‟ 
Exon 4b 5‟-GCCTGAAGAGAAACATAAAG-3‟ 5‟-GGTAATGTAAAACAAATGC-3‟ 
 104 
 
Temperatur Time Cycle 
95°C 5 min 1 
95°C 30 sec  
35 54°C 30 sec 
72°C 30 sec  
72°C 7 min 1 
 
PRIMER H-Ras (Taq : KAPA 2X (Resnova)) 
 
 PRIMER FW PRIMER RV 
Exon 2 5‟-GGTCATTAAGAGCAAGTGGG-3‟ 5‟-AGAGGAAGCAGGAGACAGG-3‟ 
Exon 3/4 5‟-AGAGGCTGGCTGTGTGAACT-3‟ 5‟-GTGTCAAGGGAGAGGGTCAG-3‟ 
Exon 5/6 5‟-AAGTGGCTGGTGGTGGAGTCG-3‟ 5‟-GGTTCCGACATACCTCATGC-3‟ 
 
 
Temperatur Time Cycle 
96°C 10 min 1 
96°C 30 sec  
45 58°C 30 sec 
72°C 30 sec  
72°C 7 min 1 
 
 
PRIMER TP53 (MgCl2 2.5mM- Fast Start Taq (Roche)) 
 
 PRIMER FW PRIMER RV 
Exon 2/3 5‟-ATCCCCACTTTTCCTCTTGC-3‟ 5‟-AGCCCAACCCTTGTCCTAC-3‟ 
Exon 4 5‟-CCTGGTCCTCTCTGACTGCTCT-3‟ 5‟-CAGGCATTGAAGTCTCATGG-3‟ 
Exon 5 5‟-CTGTCTCCTTCCTCTTCCTACAG-3‟ 5‟-AACCAGCCCTGTCGTCTCT-3‟ 
Exon 6 5‟-CAGGCCTCTGATTCCTCACT-3„ 5‟-CTTAACCCCTCCTCCCAGAC-3‟ 
Exon 7 5‟-CTCATCTTGGGCCTGTGT-3‟ 5‟-TGGAAGAAATCGGTAAGAGGTG-3‟ 
Exon 8 5‟-GGGACAGGTAGGACCTGATTT-3‟ 5‟-ATAACTGCACCCTTGGTCTCC-3‟ 
Exon 9 5‟-GGGACAGGTAGGACCTGATTT-3‟ 5‟-TCAGGCAAAGTCATAGAACCA-3‟ 
Exon 10 5‟-AACTTGAACCATCTTTTAACTCAGC-3‟ 5‟-GGAATCCTATGGCTTTCCAAC-3‟ 
Exon 11 5‟-GTCATCTCTCCTCCCTGCTTC-3 5‟-CACAACAAAACACCAGTGCAG-3‟ 
 
Temperatur Time Cycle 
95°C 10 min 1 
94°C 30 sec  
14+35 (Touch 
down) 
60-53°C 30 sec 
72°C 45 sec  
72°C 7 min 1 
 
 
PRIMER FLCN (Master Mix Taq GOLD (Applied Biosystem)) 
 
 PRIMER FW PRIMER RV 
Exon 4 5‟-GGGAGGTTTCATGGAGTCAA-3‟ 5‟-ACTGCAGGGATCACAAAACC-3‟ 
Exon 5 5‟-ACTGCAGGGATCAACAAAACC-3‟ 5‟-GAGCACCTGGGAGCATG-3‟ 
Exon 6 5‟-TGGTGTCACTAAGCGCGGAA-3‟ 5‟-TGTAAGCCAGAGGGGAAGACG-3‟ 
Exon 7 5‟-TTAAAGAGGCCATCCCTTCC-3‟ 5‟-CCTAAGAGATATGCCAAAAGC-3‟ 
 105 
Exon 8 5‟-GTGAGCGTCAGGTTTGCTTT-3‟ 5‟-CCTCCCTCAGCGATTCCT-3‟ 
Exon 9 5‟-TTGGGCTGAAGTCACAGGAT-3‟ 5‟-GCTCTCCTCCTGAGCTCCT-3‟ 
Exon 10 5‟-AGAAAAACCATTTCTAGTC-3‟ 5‟-ACCTTGGCATCCCCACCT-3‟ 
Exon 11 5‟-CGTGTGGGGTTTGGGTAGTA-3‟ 5‟-TTCCACTTTGGGCCTGAG-3‟ 
Exon 12/13 5‟-CACGGGCCTTGTGTTGTTAC-3‟ 5‟-CCTCACCCACACTGTTGCTT-3‟ 
Exon 14 5‟-GGATTGTGCTGTGGTGTCTG-3‟ 5‟-AGCTCCTTCCAGCAGTTGAG-3‟ 
 
 
Temperatur Time Cycle 
95°C 5 min 1 
94°C 30 sec  
35  56°C 45 sec 
72°C 45 sec  
72°C 10 min 1 
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ABSTRACT 
The first aims of this study were to demonstrate if mitochondrial biogenesis and 
senescence can be induced simultaneously in  cell lines upon exposure to a 
genotoxic stress, and if the presence of  mtDNA mutations which impair the 
functionality of respiratory complexes can influence the ability of a cell to activate 
senescence.  The data obtained on the oncocytic model XTC.UC1 demonstrated 
that the presence of mitochondrial dysfunction is involved in the maintenance of a 
senescent phenotype induced by γ-rays treatment. The involvement of mTORC1 
in the regulation of senescence has been shown in this cell line. On the other hand, 
in cells which do not present mitochondrial dysfunction it has been verified that  
genotoxic stress determines the activation of both mitochondrial biogenesis and 
senescence. Further studies are necessary in order to verify if mitochondrial 
biogenesis sustains the activation of senescence. 
The second aim of this thesis was to determine the involvement of mTORC1 in 
the regulation of PGC-1α expression, in order to verify what is the cause of the 
development of oncocytoma in patients affected by two hereditary cancer 
syndromes; Cowden and Birt-hogg-Dubé . The study of oncocytic tumors 
developed by patients affected by these syndromes suggested that the double 
heterozigosity of the two causative genes, PTEN and FLCN respectively, induce 
the activation of mTORC1 and therefore the activation of PGC-1α expression. On 
XTC.UC1 cell line, the most suitable in vitro model, experiments of 
complementation of PTEN and FLCN were conducted. To date, these results 
demonstrated that mTORC1 is not involved in the regulation of PGC-1α 
expression, and PTEN and FLCN seem to have opposite effect on PGC-1α 
expression functions 
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